select count(*) as counts from cancer where lower(`biomolecule`) LIKE '%rna%' && lower(`biomolecule`) NOT LIKE 'mirna%' This page shows data for RNA biomolecule.
Browse Biomarkers Based on Biomolecules
This page shows data for RNA biomolecule.
Total Entries Retrieved: 507
ID | Biomarker | Biomolecule | Subjects | Regulation | Type | Experiment | Level of Significance | Source | PMID |
---|---|---|---|---|---|---|---|---|---|
14 | MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2 | mRNA | Humans | Differentially Expressed in Recurrent Cancer | Prognostic | Recurrence Vs No Recurrence | p<0.0001 | Tissue | 15067324 |
15 | MGC5466+CHAF1A+CDS2+IER3 | mRNA | Humans | Differentially Expressed in Recurrent Cancer | Prognostic | Recurrence Vs No Recurrence | p<0.0001 | Tissue | 15067324 |
16 | PPFIA3+COPEB+FOS+JUNB+ZFP36 | mRNA | Humans | Differentially Expressed in Recurrent Cancer | Prognostic | Recurrence Vs No Recurrence | p=0.001 | Tissue | 15067324 |
17 | MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2+CHAF1A+CDS2+IER3+PPFIA3+COPEB+FOS+JUNB+ZFP36 | mRNA | Humans | Differentially Expressed in Recurrent Cancer | Prognostic | Recurrence Vs No Recurrence | p<0.0001 | Tissue | 15067324 |
19 | XLKD1/LYVE1 | mRNA | Humans | Downregulated in PCa(atleast 2 fold) | Diagnostic | Normal Prostate vs Prostate Cancer | p<0.05 | Tissue | 14654526 |
20 | CGA | mRNA | Humans | Downregulated in PCa(atleast 2 fold) | Diagnostic | Normal Prostate vs Prostate Cancer | p<0.05 | Tissue | 14654526 |
21 | F2R/PAR1 | mRNA | Humans | Downregulated in PCa(atleast 2 fold) | Diagnostic | Normal Prostate vs Prostate Cancer | p<0.05 | Tissue | 14654526 |
22 | BCL-G | mRNA | Humans | Downregulated in PCa(atleast 2 fold) | Diagnostic | Normal Prostate vs Prostate Cancer | p<0.05 | Tissue | 14654526 |
23 | XLKD1/LYVE1+CGA+ F2R/PAR1+ BCL-G | mRNA | Humans | Differentially Expressed | Prognostic | Patients with Relapse Vs Without Relapse | p<0.05 | Tissue | 14654526 |
29 | Alpha Methylacyl Coenzyme A Racemase (AMACR) | mRNA | Humans | Upregulated in Localised Prostate Cancer (3.1 fold) | Diagnostic | Benign Prostate vs Localised Prostate Cancer | p<0.001 | Tissue | 11926890 |
30 | Alpha Methylacyl Coenzyme A Racemase (AMACR) | mRNA | Humans | Upregulated in Metastatic Prostate Cancer (1.67 fold) | Diagnostic | Benign Prostate vs Metastatic Prostate Cancer | p<0.004 | Tissue | 11926890 |
43 | Fatty Acid Synthase (FAS) | mRNA | Humans | Upregulated in PCa (3 fold) [Mean Value: PCa:158 Vs Normal: 53] | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.00000029 | Tissue | 12939396 |
44 | Fatty Acid Synthase (FAS) | mRNA | Humans | Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8] | Prognostic | Gleason Score 7 Vs Metastatic Tumor | p<0.00000029 | Tissue | 12939396 |
50 | GalNAc-T3+PSMA+Hepsin+DD3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs benign prostatic hyperplasia | NA | Tissue | 15609297 |
51 | PSMA+Hepsin+DD3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs benign prostatic hyperplasia | NA | Tissue | 15609297 |
52 | GalNAc-T3+Hepsin+DD3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs benign prostatic hyperplasia | NA | Tissue | 15609297 |
53 | GalNAc-T3,+Hepsin+PSMA | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs benign prostatic hyperplasia | NA | Tissue | 15609297 |
54 | GalNAc-T3+PSMA+DD3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs benign prostatic hyperplasia | NA | Tissue | 15609297 |
55 | DDR/PCA3 | mRNA | Humans | Upregulated (140 fold) | Diagnostic | Prostate Cancer Vs benign prostatic hyperplasia | p=0.007 | Tissue | 15609297 |
56 | HEPSIN | mRNA | Humans | Upregulated (21 fold) | Diagnostic | Prostate Cancer Vs benign prostatic hyperplasia | p=0.049 | Tissue | 15609297 |
57 | PSMA | mRNA | Humans | Upregulated (66 fold) | Diagnostic | Prostate Cancer Vs benign prostatic hyperplasia | p=0.047 | Tissue | 15609297 |
58 | GalNAc-T3 | mRNA | Humans | Upregulated (4.6 fold) | Diagnostic | Prostate Cancer Vs benign prostatic hyperplasia | p=0.005 | Tissue | 15609297 |
70 | AMACR (o-methylacyl-CoA racemaÌŠse) | mRNA | Humans | Upregulated in PCa (3.3 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
71 | SIM2 (single-minded homolog 2) | mRNA | Humans | Upregulated in PCa (2.3 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
72 | EST (similar to cDS4 retroviral related polyprotein) | mRNA | Humans | Upregulated in PCa (2.3 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
73 | EST (weakly similar to protease) | mRNA | Humans | Upregulated in PCa (2.2 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
74 | TRGV9 (Tcell receptory variable 9) | mRNA | Humans | Upregulated in PCa (2.1 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
75 | EST (AGR2 anterior gradient 2 homolog) | mRNA | Humans | Upregulated in PCa (2.1 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
76 | HPN (hepsin transmembrane protease, serine I) | mRNA | Humans | Upregulated in PCa (2.0 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
77 | KCNA5 (potassium voltage-gated channel), | mRNA | Humans | Upregulated in PCa (2.0 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
78 | TM4SF13 (transmembrane 4 superfamily member 13) | mRNA | Humans | Upregulated in PCa (2.0 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
79 | SOX9 (SRY sex determining region Y-box 9) | mRNA | Humans | Upregulated in PCa (2.0 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
80 | SOX4 (SRY sex determining region Y-box 4) | mRNA | Humans | Upregulated in PCa (1.9 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
81 | SLC26A2 (solute carrier family 26 member 2) | mRNA | Humans | Upregulated in PCa (1.9 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
82 | SYNP02 (synaptopodin) | mRNA | Humans | Downregulated in PCa (4.2 fold ) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
83 | SLC18A2 (solute carrier family 18 member 2) | mRNA | Humans | Downregulated in PCa (3.0 fold ) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
84 | CALD1 (caldesmon 1) | mRNA | Humans | Downregulated in PCa (2.8 fold ) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
85 | MRE11A (meiotic recombination 11 homologue A) | mRNA | Humans | Downregulated in PCa (2.8 fold ) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
86 | KRT15 (keratin 15) | mRNA | Humans | Downregulated in PCa (2.7 fold ) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
87 | ACTG2 (actin gamma 2 smooth muscle, enteric) | mRNA | Humans | Downregulated in PCa (2.5 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
88 | DSIPI (delta sleep inducing peptide, immunoreactor) | mRNA | Humans | Downregulated in PCa (2.5 fold) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
89 | SLC18A2 (solute carrier family 18 member 2) | mRNA | Humans | Downregulated in PCa (2.5 fold ) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
90 | MME [membrane metallo-endopeptidase] | mRNA | Humans | Downregulated in PCa (2.4 fold ) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
91 | KRT17 (similar to keratin 17) | mRNA | Humans | Downregulated in PCa (2.4 fold ) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
92 | LY96 (lymphocyte antigen 96) | mRNA | Humans | Downregulated in PCa (2.4 fold ) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
93 | SYNP02 (synaptopodin) | mRNA | Humans | Downregulated in PCa (2.4 fold ) | Diagnostic | Malignant Vs Benign Tissue | p<0.05 | Tissue | 15645116 |
101 | bromo domain containing protein 2 (BRD2),+eukaryotic translation initiation factor 4 gamma 1 (EIF4G1)+ribosomal protein L22 (RPL22)+ribosomal protein L13a (RPL13a)+17 other autoantibodies | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Controls | p<0.05 | Serum | 16177248 |
102 | Methylation status of GSTP1 | mRNA | Humans | Hypermethylated in Patients who relapsed | Prognostic | Time to Progression | p<0.03 | Tissue | 16322291 |
103 | Methylation status of GSTP1 | mRNA | Humans | Hypermethylated in Patients who relapsed | Prognostic | Time to Progression | P = 0.004 | Tissue | 16322291 |
104 | Methylation status of APC | mRNA | Humans | Hypermethylated in Patients who relapsed | Prognostic | Time to Progression | P = 0.004 | Tissue | 16322291 |
105 | Methylation status of GSTP1 | mRNA | Humans | Hypermethylated in Patients who relapsed | Prognostic | Time to Progression | P = 0.01 | Tissue | 16322291 |
106 | Methylation status of Cyclin D2 + APC | mRNA | Humans | Hypermethylated in Patients who relapsed | Prognostic | Time to Progression | 0.01 | Tissue | 16322291 |
114 | PCDH7, NRXN3, TPTE/ PTEN2, EPHA3, TSPY, HGF, PKIA, PRLR, NR2F1, TNS, MET, CALN1, ADAM-TS3, NPL4, MYO3A, GNA11, GAGEB1/PA GE1, AKAP9, TCF4, MYLK, KLK2, HOXA10, DDR2, EGF, TEM8, XAGE-1, GAS2. | mRNA | Humans | Upregulated (Log2 fold change: 2-7.9 fold) | Prognostic | Androgen Independent PCa Vs Androgen Dependent PCa | NA | Cell Lines | 17977648 |
115 | ANGPT2, THBS1, CCL5, PTK6, CXCL11, S100P, PSMD5, CDKN2B, PEG3, HTATIP2, CXCL2, RND1, NK4, ACPP, ICAM1, FOSL2, SFN, PLAT, INHBE, CDKN1C, TP73, SOCS2, BMPR1B, CCL2, VIM, SPRY2, CXCL10, LCN2, AKAP12, KLF4, ATF3, FBN1, TWIST1, ALCAM, MSX2, LOX, BTG1, SOCS1, PPP3CA, PPP3CA | mRNA | Humans | Downregulated (Log2 fold change: 1.3-7.8 fold) | Prognostic | Androgen Independent PCa Vs Androgen Dependent PCa | NA | Cell Lines | 17977648 |
116 | PP2A | mRNA | Humans | Downregulated in PCa | Diagnostic | Benign Prostatic Hyperplasia (BPH) vs Prostate Cancer (PCa) | p=0.0073 | Tissue | 17977648 |
134 | Fusion Status of TMPRSS2-ERG | mRNA | Humans | Fusion of the genes in Positive Biopsy PCa | Prognostic | Positive Vs Negative Biopsies for PCa | NA | Urine | 17785564 |
135 | PCA3 | mRNA | Humans | Upregulated in Positive Biopsy PCa | Prognostic | Positive Vs Negative Biopsies for PCa | NA | Urine | 17785564 |
136 | Fusion Status of (TMPRSS2-ERG)+PCA3 | mRNA | Humans | Fused/ Upregulated in PCa | Diagnostic | Positive Vs Negative Biopsies for PCa | NA | Urine | 17785564 |
138 | CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1 | mRNA | Humans | Upregulated GEX score in PCa Patients (PCa: 7.38 ± 0.35 Vs Non Cancer: 7.2±0.16) | Diagnostic | No Cancer Vs Prostate Cancer | p=0.0013 | Tissue | 17459658 |
139 | CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1 | mRNA | Humans | Increased GEX Score with relapse | Prognostic | Relapse Vs No Relapse | p=0.007 | Tissue | 17459658 |
159 | AMACR (α-methylacyl-CoA racemåse) [AMACR 2094, 2097, 2098, 2095] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 2.12E-08 | Tissue | 16618727 |
160 | PYCR1 (Pyroline 5 - Carboxylate reductase1) | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 8.58E-10 | Tissue | 16618727 |
161 | MYO6 (Myosin VI) [MYO6-0041] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.15E-08 | Tissue | 16618727 |
162 | SMPDL3B (Sphingomyelinase like phosphodiesterase 3B) [SMPDL3B 2030] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 2.32E-08 | Tissue | 16618727 |
163 | NOX4 (NADPH oxidase 4) [NOX4 1355] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.57E-07 | Tissue | 16618727 |
164 | FASN (Fatty Acid Synthase) [FASN 1432,1433, 1435] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 4.78E-05 | Tissue | 16618727 |
165 | CACNA1D (Voltage-dep. L-type Calcium Channel Alpha 1D Subunit) [CACNA1D 2040, 2039] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 3.32E-06 | Tissue | 16618727 |
166 | FBP1 (Fructose 1,6 Bisphosphatase 1) [FBP1 0807] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.46E-07 | Tissue | 16618727 |
167 | IMPDH2 (Inosine-5′-monophosphate dehydrogenase 2) [IMPDH2 0144,0145] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.68E-05 | Tissue | 16618727 |
168 | ABCC4 (Multidrug Resistance-Associated Protein 4) [ABCD4 2013] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.09E-05 | Tissue | 16618727 |
169 | GART (Phosphoribosylglycinamide Formyltransferase) [GART 0310, 0307] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.57E-05 | Tissue | 16618727 |
170 | CLN3 (ceroid lipofuscinosis, neuronal 3, juvenile) [CLN3 1132] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.50E-05 | Tissue | 16618727 |
171 | DHPS (Deoxyhypusine Synthase) [DHPS 2028] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.68E-05 | Tissue | 16618727 |
172 | BIRC5 (Baculoviral IAP Repeat Containing 5 (survivin)) [BIRC5 0847] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.73E-05 | Tissue | 16618727 |
173 | REPS2 (RALBP1 Associated Eps Domain Containing 2) [REPS2 0732, 0733] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 2.18E-05 | Tissue | 16618727 |
174 | RPS2 (40S Ribosomal Protein S2) [RPS2-0809] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.051607 | Tissue | 16618727 |
175 | TMSNB (Thymosin, Beta, identified in neuroblastoma cells) [TMSNB 0227] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 2.34E-05 | Tissue | 16618727 |
176 | EPB41 (Erythrocyte Membrane Protein Band 4.1) [EPB41 1096,1092] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 2.69E-05 | Tissue | 16618727 |
177 | GCNT1 (Core 2 Beta1,6 N-Acetylglucosaminyltransferase-I) [GCNT1 0981, 0982,0985] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 8.15E-05 | Tissue | 16618727 |
178 | LYPLA1 (Lysophospholipase 1) [LYPLA1 0862, 0860] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.006744 | Tissue | 16618727 |
179 | RET1 (Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret) [RET1 0252 0250] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.008659 | Tissue | 16618727 |
180 | HSPD1 (Heat Shock 60kDa Protein 1 (Chaperonin)) [HSPD1 0152, 0154] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.033554 | Tissue | 16618727 |
181 | MAPT (Microtubule Associated Protein Tau) [MAPT 1060] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.000885 | Tissue | 16618727 |
182 | C7ORF24 (Chromosome 7 Open Reading Frame 24) [C7ORF24 0.001028] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.001028 | Tissue | 16618727 |
183 | ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3) [ERBB3 1431] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.001238 | Tissue | 16618727 |
184 | PLA2G2A (Phospholipase A2 Group IIA) [PLA2G2A 1380] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.001569 | Tissue | 16618727 |
185 | NME1 (Nucleoside Diphosphate Kinase A) [NME1 0827] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.001945 | Tissue | 16618727 |
186 | CDK7 (Cyclin Dependent Kinase 7) [CDK7 0899] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.002319 | Tissue | 16618727 |
187 | MMP9 (Matrix Metallopeptidase 9) [MMP9 1185] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.00262 | Tissue | 16618727 |
188 | BGN (Biglycan) [BGN 1274] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.002956 | Tissue | 16618727 |
189 | PPIB (Peptidylprolyl Isomerase B (Cyclophilin B)) [PPIB 0969] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.006963 | Tissue | 16618727 |
190 | IQGAP2 (IQ Motif Containing GTPase Activating Protein 2) [IQGAP2 0234] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.010253 | Tissue | 16618727 |
191 | DKFZP564B167 (DKFZP564B167 Protein) [DKFZP564B167 0717] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.015526 | Tissue | 16618727 |
192 | TMEPAI (Transmembrane Prostate Androgen- Induced Protein) [TMEPAI 2074] | mRNA | Humans | Upregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.023696 | Tissue | 16618727 |
193 | STAC (SH3 And Cysteine Rich Domain) [STAC 1045, 1044, 1047] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 4.42E-07 | Tissue | 16618727 |
194 | FGFR2 (Fibroblast Growth Factor Receptor 2) [FGFR2 0101,0095,0100,0106, 0107, 0097] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.42E-07 | Tissue | 16618727 |
195 | CDC42BPA (CDC42 Binding Protein Kinase Alpha) [CDC42BPA 1051] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.56E-08 | Tissue | 16618727 |
196 | KRT15 (keratin 15) [KRT15 1335, 1333, 1334,1341] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.60E-06 | Tissue | 16618727 |
197 | TRIM29 (Tripartite Motif Containing 29) [TRIM29 1353, 1348, 1346] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 4.38E-06 | Tissue | 16618727 |
198 | CES1 (Carboxylesterase ) [CES1 0942, 0937] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.43E-05 | Tissue | 16618727 |
199 | CLU (Clusterin) [CLU 0196, 0192, 0191] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.000272 | Tissue | 16618727 |
200 | ALDH1A2 (Aldehyde Dehydrogenase 1A2) [ALDH1A2 0004,0001, 0006] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.000266 | Tissue | 16618727 |
201 | DRR1 (Collagen and Wnt5a regulated receptor tyrosin kinase) [DRR1 - 0753] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.88E-07 | Tissue | 16618727 |
202 | ROBO1 (Roundabout, Axon Guidance Receptor, Homolog 1) [ROBO1 1419] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 2.26E-07 | Tissue | 16618727 |
203 | LTBP4 (Latent TFG Beta Binding Protein 4) [LTBP4 0752, 0747, 0742, 1519, 1518, 0745, 0748, 0746] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.002361 | Tissue | 16618727 |
204 | PGR (Progesterone Receptor) [PGR 1161, 1162] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 3.77E-06 | Tissue | 16618727 |
205 | EDNRB (Endothelin Receptor Type B) [EDNRB 1187] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.88E-06 | Tissue | 16618727 |
206 | ANGPT1 (Angiopoietin 1) [ANGPT1 1032, 1031] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 3.72E-05 | Tissue | 16618727 |
207 | IGF1 (Insulin like Growth Factor 1 Somatomedin C) [IGF1 0025] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 3.77E-06 | Tissue | 16618727 |
208 | COL6A2 (Collagen, Type VI, Alpha 2) [COL6A2 1489] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 8.16E-06 | Tissue | 16618727 |
209 | PTGDS (Prostaglandin D2 Synthase 21kDa) [PTGDS 0787] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.09E-05 | Tissue | 16618727 |
210 | ANGPTL2 (Angiopoietin-related Protein 2) [ANGPTL2 0950] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 1.20E-05 | Tissue | 16618727 |
211 | VCL (Vinculin) [VCL 1534, 0933, 0936] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.011744 | Tissue | 16618727 |
212 | GSTP1 (Glutathione S-transferase P) [GSTP1 0927, 0923] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.030854 | Tissue | 16618727 |
213 | SAT (Spermidine/Spermine N1-acetyltransferase) [SAT 0840, 0842] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.052888 | Tissue | 16618727 |
214 | TGFB2 (Transforming Growth Factor, Beta 2) [TGFB2 0085] | mRNA | Humans | Downregulated | Diagnostic | Cancerous Tissue Vs Normal Tissue | 0.095398 | Tissue | 16618727 |
215 | Endothelial cell-specific molecule 1; Protein tyrosine phosphatase receptor type-Q, CD24 antigen; Gap junction membrane channel protein alpha 1; Transmembrane 4 superfamily member 3; Serpine2; Activated leukocyte cell adhesion molecule; Fibromodulin; Plasminogen activator inhibitor 2 type A; Kelch repeat and BTB (POZ) domain containing 10 (krp1); Preproenkephalin, related sequence; Sialophorin; Thymosin beta-4; Glutamate receptor interacting protein 1; Synuclein, gamma; Hypoxanthine guanine phosphoribosyl transferase; Phosphoribosyl pyrophosphate synthetase 1; Phosphoribosyl pyrophosphate synthetase 2; UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6; Dual specificity phosphatase 5; Cytochrome P450, family 3, subfamily a, polypeptide 13; 3-hydroxy-3-methylglutaryl-Coenzyme A reductase ; Branched chain keto acid dehydrogenase E1, beta polypeptide; Cytochrome P450, subfamily 24; Plasminogen activator, urokinase; Caveolin 1; Cyclin D1; High mobility group AT-hook 1; Cxxc5; HNF-3/forkhead homolog-1; Fatty acid binding protein 4, adipocyte; Fatty acid binding protein 5, epidermal; Rabin 3; Phospholipase C, delta 4; Decay-accelarating factor; Coagulation factor II (thrombin) receptor-like 1; Nerve growth factor receptor associated protein 1; Asparagine synthetase; Dual specificity phosphatase 6; Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform; Protein tyrosine phosphatase, receptor type, N1; UDP glycosyltransferase 1 family polypeptide A2; Adenosine monophosphate deaminase 3; Stearoyl-Coenzyme A desaturase 1; Hypothetical LOC290595 (LOC290595), mRNA; Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA; Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA; Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds; | mRNA | Rat | Upregulated (Endothelial cell-specific molecule 1 (26.5 fold); Protein tyrosine phosphatase receptor type Q (19.72 fold); CD24 antigen (15.56 fold); Gap junction membrane channel protein alpha 1 (10.53 fold); Transmembrane 4 superfamily member 3 (10.4 fold); Serpine2 (8.61 fold); Activated leukocyte cell adhesion molecule (6.65 fold) ; Fibromodulin (2.62 fold); Plasminogen activator inhibitor 2 type A (2.11 fold); Kelch repeat and BTB (POZ) domain containing 10 (krp1) (36.21 fold); Preproenkephalin, related sequence (24.63 fold); Sialophorin1 (24.14 fold); Thymosin beta-4 (19.82 fold) ; Glutamate receptor interacting protein 1 (8.4 fold) ; Synuclein, gamma (6.62 fold); Hypoxanthine guanine phosphoribosyl transferase (11.45 fold); Phosphoribosyl pyrophosphate synthetase 1 (8.25 fold) ; Phosphoribosyl pyrophosphate synthetase 2 (5.37 fold); UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6 (3.4 fold); Dual specificity phosphatase 5 (2.35 fold); Cytochrome P450, family 3, subfamily a, polypeptide 13 (14.28 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (3.49 fold) ; Branched chain keto acid dehydrogenase E1, beta polypeptide (2.14 fold); Cytochrome P450, subfamily 24 (2.11 fold); Plasminogen activator, urokinase (4.68 fold); Caveolin 1 (31.05 fold) ; Cyclin D1 (7.95 fold); High mobility group AT-hook 1 (15.41 fold) ; Cxxc5 (4.25 fold); HNF-3/forkhead homolog-1 (3.08 fold); Fatty acid binding protein 4, adipocyte (34.02 fold); Fatty acid binding protein 5, epidermal (15.38 fold) ; Rabin 3 (6.46 fold); Phospholipase C, delta 4 (2.64 fold); Decay-accelarating factor (4.02 fold); Coagulation factor II (thrombin) receptor-like 1 (4.96 fold); Nerve growth factor receptor associated protein 1 (8.75 fold); Asparagine synthetase (14.65 fold); Dual specificity phosphatase 6 (11.08 fold); Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform (2.31 fold) ; Protein tyrosine phosphatase, receptor type, N1 (2.22 fold); UDP glycosyltransferase 1 family polypeptide A21 (5.93 fold); Adenosine monophosphate deaminase 3 (2.14 fold); Stearoyl-Coenzyme A desaturase 1 (25.92 fold); Hypothetical LOC290595 (LOC290595), mRNA (8.46 fold); Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA (4.76 fold); Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA (3.58 fold); Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds (3.38 fold); | Prognostic | MAT-LyLu Vs G Cell Lines | p<0.005 | Cell Lines | 17713630 |
216 | Procollagen, type XII, alpha 1; Glycoprotein Ib (platelet), beta polypeptide; Macrophage stimulating 1 (hepatocyte growth factor-like); Alpha-2-macroglobulin; Hyaluronan and proteoglycan link protein 1; Glycoprotein 38; Decorin; Vascular cell adhesion molecule 1; Clusterin; Elastin; Biglycan; Selenoprotein P, plasma, 1; T-cell receptor gamma chain; Myxovirus (influenza virus) resistance 2; Major histocompatibility complex, class II, DM alpha; MHC class Ib RT1.S3; RT1 class Ib, locus Aw2; Similar to interferon regulatory factor 7 (LOC293624), mRNA; Late gestation lung protein 1; Transgelin; Ectonucleoside triphosphate diphosphohydrolase 2; Dual specificity phosphatase 1; Cytochrome b-245, alpha polypeptide; 3-alpha-hydroxysteroid dehydrogenase; Cathepsin S; Alanyl (membrane) aminopeptidase; Dipeptidase 1 (renal); Caspase 1; B-cell translocation gene 3; CD 81 antigen; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; LIM homeobox protein 2; Lectin, galactose binding, soluble 9; apolipoprotein E; Ubiquitin carboxy-terminal hydrolase L1; Parvalbumin; Purkinje cell protein 4; Carboxylesterase 1; O-6-methylguanine-DNA methyltransferase; UDP glycosyltransferase 1 family, polypeptide A6; Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5; Growth hormone receptor; Insulin-like growth factor 1; Insulin-like growth factor binding protein 5; Peripherin 1; Arginosuccinate synthetase; Lactate dehydrogenase B; Calcium/calmodulin-dependent serine protein kinase; Aminolevulinic acid synthase 1; 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2; Alcohol Dehydrogenase 1; Phosphodiesterase 3B; Similar to kelch domain containing 3; testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA; Similar to cornichon-like protein (LOC361705), mRNA; Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA; Similar to CLN6 protein (LOC315746), mRNA; Reticulocalbin 3; Similar to CG31613-PA (LOC364716), mRNA; | mRNA | Rat | Downregulated (Procollagen, type XII, alpha 1 (2.18 fold); Glycoprotein Ib (platelet), beta polypeptide (2.5 fold); Macrophage stimulating 1 (hepatocyte growth factor-like) (2.61 fold); Alpha-2-macroglobulin (3.8 fold); Hyaluronan and proteoglycan link protein 1 (3.82 fold); Glycoprotein 38 (3.87 fold); Decorin (5.74 fold); Vascular cell adhesion molecule 1 (7.82 fold); Clusterin (8.84 fold); Elastin (12.76 fold); Biglycan (13.23 fold); Selenoprotein P, plasma, 1 (23.08 fold); T-cell receptor gamma chain (2.2 fold); Myxovirus (influenza virus) resistance 2 (2.22 fold) ; Major histocompatibility complex, class II, DM alpha (2.37 fold); MHC class Ib RT1.S3 (4.8 fold) ; RT1 class Ib , locus Aw2 (5.18 fold); Similar to interferon regulatory factor 7 (LOC293624), mRNA (6.14 fold); Late gestation lung protein 1 (2.26 fold); Transgelin (5.72); Ectonucleoside triphosphate diphosphohydrolase 2 (2.7 fold); Dual specificity phosphatase 1 (2.3 fold); Cytochrome b-245, alpha polypeptide (3.64 fold); 3-alpha-hydroxysteroid dehydrogenase (4.86 fold); Cathepsin S (2.33 fold); Alanyl (membrane) aminopeptidase (3.18 fold); Dipeptidase 1 (renal) (6.82 fold); Caspase 1 (11.12 fold); B-cell translocation gene 3 (17.35 fold); CD 81 antigen (36 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.28 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.62 fold); LIM homeobox protein 2 (5.43 fold); Lectin, galactose binding, soluble 9 (2.46 fold); apolipoprotein E (29.52 fold); Ubiquitin carboxy-terminal hydrolase L1 (16.29 fold); Parvalbumin (3.85 fold); Purkinje cell protein 4 (6.82 fold); Carboxylesterase 1 (2.16 fold); O-6-methylguanine-DNA methyltransferase (4.62 fold); UDP glycosyltransferase 1 family, polypeptide A6 (3.25 fold); Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5 (2.27 fold); Growth hormone receptor (3.12 fold); Insulin-like growth factor 1 (4.85 fold); Insulin-like growth factor binding protein 5 (5.25 fold); Peripherin 1 (7.17 fold); Arginosuccinate synthetase (12.75 fold); Lactate dehydrogenase B (15.07 fold); Calcium/calmodulin-dependent serine protein kinase (4.13 fold); Aminolevulinic acid synthase 1 (2.39 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (3.17 fold); Alcohol Dehydrogenase 1 (6.38 fold); Phosphodiesterase 3B (4.76 fold); Similar to kelch domain containing 3 testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA (2.17 fold); Similar to cornichon-like protein (LOC361705), mRNA (2.35 fold); Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA (2.81 fold); Similar to CLN6 protein (LOC315746), mRNA (3.68 fold); Reticulocalbin 3 (3.94 fold); Similar to CG31613-PA (LOC364716), mRNA (8.61 fold); | Prognostic | MAT-LyLu Vs G Cell Lines | p<0.005 | Cell Lines | 17713630 |
217 | Kelch repeat and BTB (POZ) domain containing 10 (krp1) | mRNA | Rat | Upregulated in MAT-LyLu (48 fold) | Prognostic | MAT-LyLu Vs G Cell Lines | p=0.01816 | Cell Lines | 17713630 |
218 | Endothelial cell-specific molecule 1 | mRNA | Rat | Upregulated in MAT-LyLu (23 fold) | Prognostic | MAT-LyLu Vs G Cell Lines | p=0.00995283 | Cell Lines | 17713630 |
219 | Caveolin 1 | mRNA | Rat | Upregulated in MAT-LyLu (45 fold) | Prognostic | MAT-LyLu Vs G Cell Lines | p=0.0009527 | Cell Lines | 17713630 |
229 | ENC1 + GJB1 | mRNA | Humans | Differentially Expressed | Diagnostic | Benign Prostate Vs Prostate Cancer | p<0.0005 | Tissue | 17460773 |
230 | MYO6 + AMACR | mRNA | Humans | Differentially Expressed | Diagnostic | Benign Prostate Vs Prostate Cancer | p<0.0005 | Tissue | 17460773 |
231 | TSPAN13 + PRKCBP1 | mRNA | Humans | Differentially Expressed | Diagnostic | Benign Prostate Vs Prostate Cancer | p<0.0005 | Tissue | 17460773 |
232 | C20ORF74 + DAPK1 | mRNA | Humans | Differentially Expressed | Diagnostic | Benign Prostate Vs Prostate Cancer | p<0.0005 | Tissue | 17460773 |
233 | IMAGE:396839 + ENC1 | mRNA | Humans | Differentially Expressed | Diagnostic | Benign Prostate Vs Prostate Cancer | p<0.0005 | Tissue | 17460773 |
234 | Metaclassifier: ENC1+GJB1+MYO6+AMACR+TSPAN13+PRKCBP+C20ORF74+DAPK1+IMAGE:396839 + ENC1 | mRNA | Humans | Differentially Expressed | Prognostic | Benign Prostate Vs Prostate Cancer | p<0.0005 | Tissue | 17460773 |
235 | ARL6IP+MYH11 | mRNA | Humans | Differentially Expressed | Prognostic | Primary Vs Metastatic Prostate Cancer | NA | Tissue | 17460773 |
236 | Cytokeratin 5 (CK5) | mRNA | Humans | Upregulated in Dasatinib Sensitive Cell Lines (>3 fold) | Potential Predictive | Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines | p<0.05 | Cell Lines | 18047674 |
237 | Prostate Specific Antigen (PSA) | mRNA | Humans | Downregulated in Dasatinib Sensitive Cell Lines (>3 fold) | Potential Predictive | Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines | p<0.05 | Cell Lines | 18047674 |
238 | Androgen Receptor (AR) | mRNA | Humans | Downregulated in Dasatinib Sensitive Cell Lines (>3 fold) | Potential Predictive | Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines | p<0.05 | Cell Lines | 18047674 |
243 | SPINK1 | mRNA | Humans | Upregulated in PCa | Diagnostic | Normal Vs Prostate Cancer | p=0.0002 | Urine | 18245462 |
244 | GOLPH2 | mRNA | Humans | Upregulated in PCa | Diagnostic | Normal Vs Cancer | p=0.0002 | Urine | 18245462 |
245 | PCA3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Normal Vs Cancer | p=0.001 | Urine | 18245462 |
246 | SPINK1, PCA3, GOLPH2, TMPRSS2:ERG | mRNA | Humans | Upregulated in PCa | Diagnostic | Normal Vs Cancer | p=1.91E-11 | Urine | 18245462 |
247 | SPINK1, PCA3, GOLPH2, TMPRSS2:ERG | mRNA | Humans | Upregulated in PCa | Diagnostic | Normal Vs Cancer | p=1.91E-11 | Urine | 18245462 |
248 | PI3-K p85 α | mRNA | Humans | Downregulated in Gleason Score 7-10 | Prognostic | Gleason Score 5-6 Vs Gleason Score 7-10 | p<0.05 | Tissue | 18336616 |
249 | ILK | mRNA | Humans | Downregulated in Gleason Score 7-11 | Prognostic | Gleason Score 5-6 Vs Gleason Score 7-10 | p<0.05 | Tissue | 18336616 |
250 | PTEN | mRNA | Humans | Downregulated in Gleason Score 7-12 | Prognostic | Gleason Score 5-6 Vs Gleason Score 7-10 | p<0.05 | Tissue | 18336616 |
251 | PHLPP | mRNA | Humans | Downregulated in Gleason Score 7-13 | Prognostic | Gleason Score 5-6 Vs Gleason Score 7-10 | p<0.05 | Tissue | 18336616 |
252 | FOXO1A | mRNA | Humans | Downregulated in Gleason Score 7-14 | Prognostic | Gleason Score 5-6 Vs Gleason Score 7-10 | p<0.05 | Tissue | 18336616 |
256 | TOP2A | mRNA | Humans | Upregulated in PCa (≥2 fold) | Diagnostic | Prostate Cancer Vs Nonneoplastic Sample | p<0.05 | Tissue | 18347174 |
257 | ERG | mRNA | Humans | Upregulated in PCa (≥2 fold) | Diagnostic | Prostate Cancer Vs Nonneoplastic Sample | p<0.05 | Tissue | 18347174 |
258 | NRP1 | mRNA | Humans | Upregulated in Aggressive Prostate Cancer | Prognostic | Non Aggressive Vs Aggressive prostate cancer phenotype | p=0.007 | Tissue | 18347174 |
259 | TOP2A | mRNA | Humans | Upregulated in Aggressive Prostate Cancer | Prognostic | Non Aggressive Vs Aggressive prostate cancer phenotype | p<0.0001 | Tissue | 18347174 |
260 | RRM2 | mRNA | Humans | Upregulated in Aggressive Prostate Cancer | Prognostic | Non Aggressive Vs Aggressive prostate cancer phenotype | p<0.0001 | Tissue | 18347174 |
261 | KHRDSB3 | mRNA | Humans | Upregulated in Aggressive Prostate Cancer | Prognostic | Non Aggressive Vs Aggressive prostate cancer phenotype | p=0.015 | Tissue | 18347174 |
262 | SSTR1 | mRNA | Humans | Upregulated in Aggressive Prostate Cancer | Prognostic | Non Aggressive Vs Aggressive prostate cancer phenotype | p=0.006 | Tissue | 18347174 |
263 | Methylation Status of NKX2-5 | mRNA | Humans | Hypermethylated (2.7% normal vs 14% in Cancerous condition) | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
264 | Methylation Status of CALSTN1 | mRNA | Humans | Hypermethylated (2.5% normal vs 12.1% in Cancerous condition) | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
265 | Methylation Status of SPOCK2 | mRNA | Humans | Hypermethylated (7.5% normal vs 15.2% in Cancerous condition) | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
266 | Methylation Status of NSE1 | mRNA | Humans | Hypermethylated (10.3% normal vs 20.5% in Cancerous condition) | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
267 | Methylation Status of SLC16A12 | mRNA | Humans | Hypermethylated (9% normal vs 22% in Cancerous condition) | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
268 | Methylation Status of FOXN4 | mRNA | Humans | Hypermethylated (2.4% normal vs 4.3% in Cancerous condition) | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
269 | Methylation Status of GALR2 | mRNA | Humans | Hypermethylated (2% normal vs 4.3% in Cancerous condition) | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
270 | Methylation Status of DPYS | mRNA | Humans | Hypermethylated (24.2% normal vs 42.71% in Cancerous condition) | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
271 | Methylation Status of (DPYS or NKX2-5) | mRNA | Humans | Hypermethylated in Prostate Cancer | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
272 | Methylation Status of (CALSTN1 or DYPS) | mRNA | Humans | Hypermethylated in Prostate Cancer | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
273 | Methylation Status of (NSE1 or DPYS) | mRNA | Humans | Hypermethylated in Prostate Cancer | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
274 | Methylation Status of (NSE1 or SPOCK2) | mRNA | Humans | Hypermethylated in Prostate Cancer | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
275 | Methylation Status of (SLC16A12 or DPYS) | mRNA | Humans | Hypermethylated in Prostate Cancer | Diagnostic | prostate cancer Vs normal prostate | p<0.05 | Tissue | 18446232 |
276 | Fusion Status of TMPRSS2:ERG | mRNA | Humans | Increased fusion in patients with biochemical Recurrence | Prognostic | Biochemical Recurrence Vs no Recurrence | p=0.0523 | Tissue | 18500259 |
277 | Mutation of PTEN | mRNA | Humans | Deletion found in patients with Biochemical Recurrence | Prognostic | Biochemical Recurrence Vs no Recurrence | p=0.0009 | Tissue | 18500259 |
278 | Fusion Status of TMPRSS2:ERG + PTEN deletion | mRNA | Humans | Fusion + Deletion | Prognostic | Biochemical Recurrence Vs no Recurrence | p=0.001 | Tissue | 18500259 |
279 | Fusion Status of TMPRSS2:ERG + PTEN deletion | mRNA | Humans | Fusion + Deletion | Prognostic | Biochemical Recurrence Vs no Recurrence | p=0.036 | Tissue | 18500259 |
280 | Golgi phosphoprotein 2 (GOLPH2) | mRNA | Humans | Upregulated in Prostate Cancer(3.04 fold) | Diagnostic | prostate cancer Vs normal prostate | p<0.001 | Tissue | 18543251 |
283 | Myosin VI (MYO6) | mRNA | Humans | Upregulated in Prostate Cancer | Diagnostic | Tumor and adjacent normal prostate tissues | NA | Tissue | 18543251 |
379 | TMPRSS2:ERG | mRNA | Humans | Fused in Prostate Cancer | Diagnostic | Benign vs. PCA | p<0.05 | Expressed Prostatic Secretion | 18948370 |
380 | Serum PSA + DRE + Methylation Status of RARB | mRNA | Humans | Hypermethylated in Prostate Cancer | Diagnostic | Benign vs. PCA | p<0.06 | Expressed Prostatic Secretion | 18948370 |
381 | Serum PSA + DRE + Methylation Status of (GSTP1, APC, RARB, and RASSF1) | mRNA | Humans | GSTP1, APC, RARB, and RASSF1 Hypermethylated in Prostate Cancer | Diagnostic | Benign vs. PCA | p<0.01 | Expressed Prostatic Secretion | 18948370 |
382 | Serum PSA + DRE + Methylation Status of RASSF1 | mRNA | Humans | RASSF1 Hypermethylated in Prostate Cancer | Diagnostic | Benign vs. PCA | p< 0.05 | Expressed Prostatic Secretion | 18948370 |
383 | Serum PSA + DRE + PCA3 | mRNA | Humans | NA | Diagnostic | Benign vs. PCA | p<0.01 | Expressed Prostatic Secretion | 18948370 |
384 | Serum PSA + DRE + TMPRSS:ERG | mRNA | Humans | NA | Diagnostic | Benign vs. PCA | p<0.001 | Expressed Prostatic Secretion | 18948370 |
385 | TMPRSS2:ERG | mRNA | Humans | Fused in Prostate Cancer | Prognostic | (Benign Samples + Gleason sums < 7) Vs ≥ 7 | p<0.05 | Expressed Prostatic Secretion | 18948370 |
386 | Serum PSA + DRE + Methylation Status of GSTP1 | mRNA | Humans | Hypermethylated in Prostate Cancer | Diagnostic | (Benign Samples + Gleason sums < 7) Vs ≥ 7 | p<0.05 | Expressed Prostatic Secretion | 18948370 |
387 | Serum PSA + DRE + Methylation Status of APC | mRNA | Humans | Hypermethylated in Prostate Cancer | Diagnostic | (Benign Samples + Gleason sums < 7) Vs ≥ 7 | p<0.01 | Expressed Prostatic Secretion | 18948370 |
388 | Serum PSA + DRE + Methylation Status of RARB | mRNA | Humans | Hypermethylated in Prostate Cancer | Diagnostic | (Benign Samples + Gleason sums < 7) Vs ≥ 7 | p<0.01 | Expressed Prostatic Secretion | 18948370 |
389 | Serum PSA + DRE + Methylation Status of RASSF1 | mRNA | Humans | Hypermethylated in Prostate Cancer | Diagnostic | (Benign Samples + Gleason sums < 7) Vs ≥ 7 | p<0.05 | Expressed Prostatic Secretion | 18948370 |
390 | Serum PSA + DRE + Methylation Status of (GSTP1, APC, RARB, and RASSF1) | mRNA | Humans | GSTP1, APC, RARB, and RASSF1 Hypermethylated in Prostate Cancer | Diagnostic | (Benign Samples + Gleason sums < 7) Vs ≥ 7 | p<0.05 | Expressed Prostatic Secretion | 18948370 |
391 | Serum PSA + DRE + PCA3 | mRNA | Humans | NA | Diagnostic | (Benign Samples + Gleason sums < 7) Vs ≥ 7 | p<0.01 | Expressed Prostatic Secretion | 18948370 |
392 | Serum PSA + DRE + TMPRSS2:ERG | mRNA | Humans | Fused in Prostate Cancer | Diagnostic | (Benign Samples + Gleason sums < 7) Vs ≥ 7 | p<0.001 | Expressed Prostatic Secretion | 18948370 |
393 | Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU) | mRNA | Humans | Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC) | Diagnostic | Benign Vs Prostate Cancer | Clusterin: p<0.01 | Tissue | 18974881 |
394 | Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU) | mRNA | Humans | Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC) | Prognostic | Gleason Score <7 Vs Gleason Score ≥ 7 | NA | Tissue | 18974881 |
406 | Androgen Receptor (AR) | mRNA | Humans | Upregulated in Hormone Refactory Prostate Cancer (11 fold) | Prognostic | Hormone Naive Vs Hormone Refractory Prostate Cancer | p<0.0001 | Tissue | 19117982 |
407 | Androgen Receptor AR-V1 | mRNA | Humans | Upregulated in Hormone Refactory Prostate Cancer (22 fold) | Prognostic | Hormone Naive Vs Hormone Refractory Prostate Cancer | p<0.0001 | Tissue | 19117982 |
408 | Androgen Receptor AR-V7 | mRNA | Humans | Upregulated in Hormone Refactory Prostate Cancer (20 fold) | Prognostic | Hormone Naive Vs Hormone Refractory Prostate Cancer | p<0.0001 | Tissue | 19117982 |
409 | Androgen Receptor AR-V7 | mRNA | Humans | Higher expression in patients with biochemical recurrence | Prognostic | PSA Recurrence Vs No PSA Recurrence | p=0.012 | Tissue | 19117982 |
430 | TMPRSS2 | mRNA | Humans | Upregulated in PCa: (Normal: 0.26 ± 0.04 vs PCa: 3.91 ± 0.78) | Diagnostic | prostate cancer Vs Adjacent Normal | p=0.001 | Tissue | 19242826 |
431 | TMPRSS2 | mRNA | Humans | Upregulated (Clinical Stage 1&2: 3.43 ± 0.62 ; Vs Clinical Stage 3: 5.45 ± 0.92) | Prognostic | Clincal Stage (1-2) Vs Clinical Stage 3 | p=0.02 | Tissue | 19242826 |
432 | TMPRSS2 | mRNA | Humans | Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53) | Prognostic | Gleason Score ≤6, Vs Gleason Score>6 | p=0.008 | Tissue | 19242826 |
433 | TMPRSS2 | mRNA | Humans | Upregulated (Tumor Grade 1-2: 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31) | Prognostic | Tumor Grade (1-2) Vs Tumor Grade 3 | p=0.016 | Tissue | 19242826 |
434 | KLK11 | mRNA | Humans | Upregulated in PCa: (Normal: 0.49 ± 0.07 vs PCa: 3.63 ± 0.42) | Diagnostic | prostate cancer Vs Adjacent Normal | p=0.003 | Tissue | 19242826 |
435 | KLK11 | mRNA | Humans | Upregulated (CS: (1-2) 6.05 ± 1.34 vs CS 3: 3.93 ± 0.45) | Prognostic | Clincal Stage (1-2) Vs Clinical Stage 3 | p=0.009 | Tissue | 19242826 |
436 | KLK11 | mRNA | Humans | Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53) | Prognostic | Gleason Score ≤6, Vs Gleason Score>6 | p=0.01 | Tissue | 19242826 |
437 | KLK11 | mRNA | Humans | Upregulated (Tumor Grade 1-2 : 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31) | Prognostic | Tumor Grade (1-2) Vs Tumor Grade 3 | p=0.006 | Tissue | 19242826 |
442 | ACPP; AD-017; AMIGO2; APPBP2; ASNS; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10; C1orf9; C22orf18 (CENPM); C5orf13; C6orf111; C6orf210; C9orf116; C9orf127; CATSPER2; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2; CDC20; CDC25C; CDC6; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1; EFNB2; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1; GALNT7; GFPT1; GGA2; GTSE1; GTSE1; H2AFX; H2AFY; HCAP-G; HCAP-G; HECA; HMGB2; HMMR; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A KLK2; KLK2; KLK3; KNS2; KNTC2; LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5 ; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10; MYRIP; NAP1L3; NAV3; NEK2; NEK2 NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A; PDIR; PER3; PIK3R1;PINK1; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B; RACGAP1; RBM30; RFC3; RRM1 ; RRM2; RRM2; SAS; SDC2 ; SDC2 ; SDC4; SEC6L1; SHCBP1 ; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2; STK3; STK6 ; TM4SF1; TMPO; TNFRSF10B ; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK; TPBG; TPX2; TRIB1; TTC3; TUBA3; TYMS; UAP1; UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT | mRNA | Humans | Differentially Expressed | Prognostic | Metastatic Vs Localised Prostate Cancer | p=0.0000121714 | Cell Lines | 19351846 |
443 | ACPP; AD-017 ; AMIGO2; APPBP2; ASNS ; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10 ; C1orf9; C22orf18 (CENPM) ; C5orf13; C6orf111 ; C6orf210; C9orf116 ; C9orf127; CATSPER2 ; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2 ; CDC20; CDC25C ; CDC6 ; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1 ; EFNB2 ; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1 ; GALNT7; GFPT1 ; GGA2; GTSE1; GTSE1 ; H2AFX ; H2AFY; HCAP-G; HCAP-G ; HECA; HMGB2; HMMR ; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A; KLK2 ; KLK2 ; KLK3; KNS2 KNTC2 LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10 MYRIP; NAP1L3; NAV3 ; NEK2; NEK2; NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A ; PDIR; PER3 ; PIK3R1 ; PINK1 ; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B ; RACGAP1;RBM30; RFC3; RRM1; RRM2; RRM2; SAS ; SDC2; SDC2 ; SDC4; SEC6L1; SHCBP1; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2 ; STK3; STK6; TM4SF1 ; TMPO; TNFRSF10B; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK ; TPBG; TPX2; TRIB1 ; TTC3; TUBA3; TYMS; UAP1;UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT | mRNA | Humans | Differentially Expressed | Prognostic | Androgen Dependent Vs Androgen Independent Prostate Cancer | p=0.0056 | Cell Lines | 19351846 |
444 | Differential display 3 (DD3/PCA3) | mRNA | Humans | Upregulated in PCa (37 fold) | Diagnostic | Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa) | p=0.0001 | Urine | 19489685 |
445 | Urinary PSA | mRNA | Humans | Upregulated | Diagnostic | Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa) | p=0.0001 | Urine | 19489685 |
446 | DD3 +PSA | mRNA | Humans | Upregulated | Diagnostic | Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa) | p<0.0001 | Urine | 19489685 |
474 | CCNB1 (cyclin B1); CENPF (centromere protein F, 350/400 ka (mitosin)); BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)); CLDN4 (claudin 4); KIAA0101 (KIAA0101); LOC400879 (Hypothetical gene supported by AK096951); SLC39A6 (solute carrier family 39 (zinc transporter), member 6); SOX4 (SRY (sex determining region Y)-box 4); TOP2A (topoisomerase (DNA) II alpha 170 kDa) | mRNA | Humans | Upregulated: CCNB1 (cyclin B1) [1.8 fold]; CENPF (centromere protein F, 350/400 ka (mitosin)) [1.4 fold]; BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)) [1.4 fold]; CLDN4 (claudin 4) [2.4 fold]; KIAA0101 (KIAA0101) [1.6 fold]; LOC400879 (Hypothetical gene supported by AK096951) [1.7 fold]; SLC39A6 (solute carrier family 39 (zinc transporter), member 6) [1.6 fold]; SOX4 (SRY (sex determining region Y)-box 4) [1.8 fold]; TOP2A (topoisomerase (DNA) II alpha 170 kDa) [1.7 fold] | Diagnostic | Tumor Vs Adjacent To Tumor | p=0.05 | Tissue | 19652763 |
475 | ABLIM3 (actin binding LIM protein family, member 3); AOX1 (aldehyde oxidase 1); CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)); DSCR1 (Down syndrome critical region gene 1); GLRX (glutaredoxin (thioltransferase)); IGFBP4 (insulin-like growth factor binding protein 4); MT1B (metallothionein 1B); MT1E (metallothionein 1E); MT1F (metallothionein 1F); MT1H (metallothionein 1H); C1QB (complement component 1, q subcomponent, B chain); CYB5R3 (cytochrome b5 reductase 3); DARC (Duffy blood group, chemokine receptor); DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)); F13A1 (coagulation factor XIII, A1 polypeptide); FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)); G0S2 (G0/G1switch 2); GAS6 (growth arrest-specifi c 6); IFITM2 (interferon induced transmembrane protein 2 (1–8D)); ITGA1 (integrin, alpha 1); MAP4 (microtubule-associated protein 4); MT1A (metallothionein 1A); MT2A (metallothionein 2A); PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase); PROS1 (protein S (alpha)); RBPMS (RNA binding protein with multiple splicing); RDX (Radixin); RNF11 (ring finger protein 11); S100A8 (S100 calcium binding protein A8); SERINC1 (serine incorporator 1); SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)); STOM (stomatin); TGFBR3 (transforming growth factor, beta receptor III); TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)); WDR47 (WD repeat domain 47) | mRNA | Humans | Downregulated: ABLIM3 (actin binding LIM protein family, member 3) [1.6 fold]; AOX1 (aldehyde oxidase 1) [2.6 fold]; CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)) [1.7 fold]; DSCR1 (Down syndrome critical region gene 1) [1.6 fold]; GLRX (glutaredoxin (thioltransferase)) [1.7 fold]; IGFBP4 (insulin-like growth factor binding protein 4) [2.5 fold]; MT1B (metallothionein 1B) [2.3 fold]; MT1E (metallothionein 1E) [1.9 fold]; MT1F (metallothionein 1F) [2.3 fold]; MT1H (metallothionein 1H) [2.4 fold]; C1QB (complement component 1, q subcomponent, B chain) [1.4 fold]; CYB5R3 (cytochrome b5 reductase 3) [1.4 fold]; DARC (Duffy blood group, chemokine receptor) [2.9 fold]; DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)) [1.4 fold]; F13A1 (coagulation factor XIII, A1 polypeptide) [2.1 fold]; FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)) [1.6 fold]; G0S2 (G0/G1switch 2) [2.2 fold]; GAS6 (growth arrest-specifi c 6) [2 fold]; IFITM2 (interferon induced transmembrane protein 2 (1–8D)) [2 fold]; ITGA1 (integrin, alpha 1) [1.4 fold]; MAP4 (microtubule-associated protein 4) [1.6 fold]; MT1A (metallothionein 1A) [2.6 fold]; MT2A (metallothionein 2A) [2.5 fold]; PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase) [1.3 fold]; PROS1 (protein S (alpha)) [1.7 fold]; RBPMS (RNA binding protein with multiple splicing) [2.4 fold]; RDX (Radixin) [1.4 fold]; RNF11 (ring finger protein 11) [1.4 fold]; S100A8 (S100 calcium binding protein A8) [2.3 fold]; SERINC1 (serine incorporator 1) [1.5 fold]; SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)) [2.2 fold]; STOM (stomatin) [1.8 fold]; TGFBR3 (transforming growth factor, beta receptor III) [1.7 fold]; TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)) [1.8 fold]; WDR47 (WD repeat domain 47) [1.5 fold] | Diagnostic | Tumor Vs Adjacent To Tumor | p=0.05 | Tissue | 19652763 |
486 | PSGR (Prostate-Specific G-protein Coupled Receptor) | mRNA | Humans | Upregulated | Diagnostic | Benign Vs Prostate Cancer | p=0.008 | Urine | 20672322 |
487 | PCA3 (Prostate Cancer Gene 3) | mRNA | Humans | Upregulated | Diagnostic | Benign Vs Prostate Cancer | p<0.001 | Urine | 20672322 |
488 | PSGR + PCA3 | mRNA | Humans | Upregulated | Diagnostic | Benign Vs Prostate Cancer | NA | Urine | 20672322 |
489 | PCA3 (Prostate Cancer Gene 3) | mRNA | Humans | Upregulated in Positive Biopsy | Diagnostic | Positive PCa Biopsy Vs Negative PCa Biopsy | p <0.0001 | Urine | 20850153 |
490 | Age+ Family History+ PCA3 + %fPSA+ Prostate Volume+ sPSA | mRNA | Humans | Upregulated in Positive Biopsy | Diagnostic | Positive PCa Biopsy Vs Negative PCa Biopsy | p <0.0001 | Urine | 20850153 |
491 | Age+ Family History+ PCA3 + %fPSA+ Prostate Volume+ sPSA | mRNA | Humans | Upregulated in Positive Biopsy | Diagnostic | Positive PCa Biopsy Vs Negative PCa Biopsy | p <0.0001 | Urine | 20850153 |
503 | ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1; | mRNA | Humans | Differentially Expressed: ANXA5 [1.47 fold]; APLP2 [1.22 fold]; COL1A2 [1.18 fold]; CRIM1 [1.20 fold]; ECHS1 [1.18 fold]; HMGB1 [1.40 fold]; MAP3K5 [1.35 fold]; NGFRAP1 [1.32 fold]; NPM1 [1.30 fold]; NUB1 [1.12 fold]; PDIA3 [1.43 fold]; PLA2G2A [1.75 fold]; ROCK1 [1.17 fold]; TEGT [1.32 fold]; TMEM16G [0.66 fold]; TMEM69 [1.08 fold]; TRAF4 [1.26 fold]; VCAN [1.31 fold]; VCP [1.18 fold]; VDAC1 [1.51 fold]; | Prognostic | Gleason Score 6 Vs Gleason Score (8-10) | p<0.05 | Tissue | 20035634 |
504 | ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1; | mRNA | Humans | Differentially Expressed: ANXA5 [4.28 fold]; APLP2 [2.83 fold]; COL1A2 [2.02 fold]; CRIM1 [3.23 fold]; ECHS1 [1.89 fold]; HMGB1 [4.68 fold]; MAP3K5 [2.98 fold]; NGFRAP1 [3.95 fold]; NPM1 [3.07 fold]; NUB1 [1.62 fold]; PDIA3 [2.40 fold]; PLA2G2A [3.00 fold]; ROCK1 [9.76 fold]; TEGT [2.77 fold]; TMEM16G [0.35 fold]; TMEM69 [2.77 fold]; TRAF4 [2.59 fold]; VCAN [2.92 fold]; VCP [2.75 fold]; VDAC1 [5.41 fold]; | Prognostic | Gleason Score 6 Vs Gleason Score (8-10) | p<0.05 | Tissue | 20035634 |
505 | MAP3K5 | mRNA | Humans | Upregulated in Gleason Score 8-10 | Prognostic | Gleason Score 6 Vs Gleason Score (8-10) | qRT-PCR: p=0.0129 | Tissue | 20035634 |
506 | PDIA3 | mRNA | Humans | Upregulated in Gleason Score 8-10 | Prognostic | Gleason Score 6 Vs Gleason Score (8-10) | qRT-PCR: p=0.00167 | Tissue | 20035634 |
507 | TRPM8 (transient receptor potential member 8) | mRNA | Humans | Upregulated in PCa | Diagnostic | Tumors Vs patient matched non-tumor | NA | Tissue | 20043080 |
508 | TRPM8 (transient receptor potential member 8) | mRNA | Humans | Upregulated in PCa (ratio = 1.94±0.256) | Diagnostic | Tumors Vs patient matched non-tumor | p<0.01 | Tissue | 20043080 |
509 | TRPM8 (transient receptor potential member 8) | mRNA | Humans | Upregulated in Metastatis (Metastatis: 1.81±0.153; Healthy: 1.0 ± 0.132) | Diagnostic | Healthy Vs Metastatic | p<0.001 | Blood | 20043080 |
510 | TRPM8 (transient receptor potential member 8) | mRNA | Humans | Upregulated in Metastatis | Diagnostic | Healthy Vs Metastatic | p<0.0001 | Urine | 20043080 |
511 | TMPRSS2–ERG | mRNA | Humans | Fusion Positive in Recurrence | Prognostic | Biochemical recurrence Vs No recurrence | p=0.0000000354 | Tissue | 20068566 |
512 | ERG expression in TMPRSS2–ERG | mRNA | Humans | Upregulated in Fusion (3.07-fold) | Prognostic | ERG Fusion Vs No Fusion | p=3.48E-11 | Tissue | 20068566 |
513 | CSPG2+ WNT10B+E2F3+CDKN2A+TYMS+TGFB3+ALOX12+CD44+LAF4 | mRNA | Humans | Upregulated with Biochemical Recurrence | Prognostic | Biochemical recurrence Vs No recurrence | Univariate: p=0.0000002; Multivariate: p=0.0270 | Tissue | 20068566 |
514 | Enhancer of Zeste 2 (EZH2) | mRNA | Humans | Overexpression leads to aggressive behaviour in Cell Lines | Prognostic | Overexpression Vs No Overexpression in Cell Lines | NA | Cell Lines | 20087897 |
531 | KLK15 (kallikrein-related peptidase) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Normal Adjacent | p = 0.045 | Tissue | 20473923 |
538 | SPATA19 | mRNA | Humans | Upregulated in PCa (Increased Prostate cancer risk with High expression) | Diagnostic | Benign Prostatic Hyperplasia Vs Prostate Cancer | p<0.0001 | Tissue | 20682177 |
539 | LEMD1 | mRNA | Humans | Upregulated in PCa (Increased Prostate cancer risk with High expression) | Diagnostic | Benign Prostatic Hyperplasia Vs Prostate Cancer | p=0.012 | Tissue | 20682177 |
543 | PCA3 | mRNA | Humans | Differentially Expressed | Diagnostic | Cancer Vs No Malignancy (PSA Range: 4-10) | Univariate: p=0; Multivariate: p=0.02 | Urine | 20957673 |
544 | TMPRSS2: ERG | mRNA | Humans | Differentially Expressed | Diagnostic | Cancer Vs No Malignancy (PSA Range: 4-10) | Univariate: p=0.002; Multivariate: p=0.028 | Urine | 20957673 |
547 | PCA3 | mRNA | Humans | Differentially Expressed | Diagnostic | Cancer Vs No Malignancy | Univariate: p=0; Multivariate: p=0.02 | Urine | 20957673 |
548 | TMPRSS2: ERG | mRNA | Humans | Differentially Expressed | Diagnostic | Cancer Vs No Malignancy | Univariate: p=0.002; Multivariate: p=0.028 | Urine | 20957673 |
561 | C8orf4; TMC5; PDLIM5; JAG1; HOXA9; C4A; STEAP4; HLA-DMB; COL12A1; DHRS8; C10orf137; SLC7A1; PDZRN3; F3; ACER3; POLB; PXDN; PROM2; GUCY1A3; SOX4; | mRNA | Humans | Upregulated (Fold Change): [C8orf4 (5.14 fold); TMC5 (4.83 fold) ; PDLIM5 (4.51 fold); JAG1 (4.36 fold); HOXA9 (4.25 fold) ; C4A (3.98 fold); STEAP4 (3.92 fold); HLA-DMB (3.85fold); COL12A1 (3.81 fold); DHRS8 (3.81 fold); C10orf137 (3.62 fold); SLC7A1 (3.44 fold); PDZRN3 (3.30 fold); F3 (3.26 fold) ; ACER3 (3.17fold); POLB (3.16 fold); PXDN (3.12 fold); PROM2 (3.11 fold); GUCY1A3 (3.10 fold); SOX4 (3.02 fold);] | Diagnostic | High BMI Tumor Vs High BMI Normal | p<0.05 | Tissue | 21060327 |
562 | ACADL; PHLDA2; GPD1; L; NTAN1; LOC389048; SFN; HSRG1; PAK1IP1; EBP; ANPEP; ANTXR2; COL4A6; LOC400880; RHOU; GREB1; FLJ30428; C3orf14; ZNF532; SCD; PTN; SC4MOL; MAF; NPAL3; CYP3A5; NOV; ALOX15B; LOC399959; VGL-3; INSIG1; Rcan3; Poteg; P704P; EFS; | mRNA | Humans | Downregulated (Fold Change): [ACADL (0.33 fold); PHLDA2 (0.33 fold); GPD1L (0.33 fold); NTAN1 (0.33 fold); LOC389048 (0.32 fold); SFN (0.32 fold); HSRG1 (0.32 fold); PAK1IP1 (0.32 fold); EBP (0.31 fold); ANPEP (0.31 fold); ANTXR2 (0.29 fold); COL4A6 (0.29 fold); LOC400880 (0.29 fold); RHOU (0.29 fold); GREB1 (0.28 fold); FLJ30428 (0.27 fold); C3orf14 (0.27 fold); ZNF532 (0.26 fold); SCD (0.25 fold); PTN (0.24 fold); SC4MOL (0.24 fold); MAF (0.22 fold); NPAL3 (0.22 fold); CYP3A5 (0.21 fold); NOV (0.20 fold); ALOX15B (0.17 fold); LOC399959 (0.17 fold); VGL-3 (0.16 fold); INSIG1 (0.16 fold); Rcan3 (0.15 fold); Poteg (0.14 fold); P704P (0.13 fold); EFS (0.13 fold)] | Diagnostic | High BMI Tumor Vs High BMI Normal | p<0.05 | Tissue | 21060327 |
582 | GSTP1, BCL2, ADCY4, CACNA1G, LOC63928, and D4S234E | mRNA | Humans | Downregulated | Diagnostic | Tumor Vs Tumor Adjacent | p<0.05 | Tissue | 21237555 |
584 | SLCO1B1; SLCO1B3; SLCO2A1; SLCO3A1; | mRNA | Humans | Upregulated in CRPC metastases: SLCO1B1 (5.5 fold); SLCO1B3( 3.6 fold); SLCO2A1 (3.2 fold); SLCO3A1 (5.4 fold); | Prognostic | CRPC metastases versus untreated prostate cancer | p<0.053 | Tissue | 21266523 |
597 | Engrailed-2 (EN2) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Controls | p<0.05 | Cell Lines | 21364037 |
644 | PSMA | mRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Benign | p=0.016 | Urine | 21520154 |
645 | PSGR | mRNA | Humans | Upregulted in PCa | Diagnostic | Prostate Cancer Vs Benign | p<0.001 | Urine | 21520154 |
646 | PCA3 | mRNA | Humans | Upregulted in PCa | Diagnostic | Prostate Cancer Vs Benign | p=0.018 | Urine | 21520154 |
647 | PSMA + PSGR + PCA3 | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Benign | NA | Urine | 21520154 |
648 | PSMA + PSGR + PCA3 + PSA | mRNA | Humans | Differentially Expressed | Diagnostic | (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml | NA | Urine | 21520154 |
649 | PSMA | mRNA | Humans | Downregulated in PCa | Diagnostic | (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml | p=0.003 | Urine | 21520154 |
650 | PSGR | mRNA | Humans | Upregulted in PCa | Diagnostic | (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml | p= 0.009 | Urine | 21520154 |
651 | PCA3 | mRNA | Humans | Upregulted in PCa | Diagnostic | (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml | p=0.025 | Urine | 21520154 |
652 | PSMA + PSGR + PCA3 | mRNA | Humans | Differentially Expressed | Diagnostic | (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml | NA | Urine | 21520154 |
658 | PCA3 | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs No Prostate cancer | p=0.001 | Urine | 21600800 |
659 | PSA | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs No Prostate cancer | p=0.019 | Urine | 21600800 |
660 | TMPRSS2:ERG | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs No Prostate cancer | p=0.001 | Urine | 21600800 |
661 | PSA +PCA3 + TMPRSS2:ERG | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs No Prostate cancer | NA | Urine | 21600800 |
662 | TMPRSS2:ERG+ PCA3 | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs No Prostate cancer | NA | Urine | 21600800 |
673 | Androgen Receptor | mRNA | Humans | Downregulated in PCa | Diagnostic | Tumor Vs Normal Tissues | p=0.018 | Tissue | 21667031 |
688 | PCA3 | mRNA | Humans | Upregulated in Prostate Cancer | Diagnostic | Prostate Cancer Vs Non- Prostate Cancer | p<0.001 | Urine | 21788966 |
689 | PCA3 | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Non- Prostate Cancer | p=0.04 | Urine | 21788966 |
690 | AMACR | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Non- Prostate Cancer | p=0.04 | Urine | 21788966 |
691 | Multiplex Model (PCA3+ AMACR+ SPINK1+ EZH2+ GOLM1+ TRPM8 + MSMB + Serum PSA) | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Non- Prostate Cancer | p<0.001 | Urine | 21788966 |
692 | Quadriplex Model (TRPM8 + MSMB+ PCA3+ AMACR) | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Non- Prostate Cancer | p<0.001 | Urine | 21788966 |
693 | Triplex Model (TRPM8 + MSMB+AMACR) | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Non- Prostate Cancer | p<0.001 | Urine | 21788966 |
694 | Duplex Model (TRPM8 + MSMB) | mRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Non- Prostate Cancer | p=0.01 | Urine | 21788966 |
695 | AMACR | mRNA | Humans | Upregulated in locally advanced cancers | Prognostic | localized Vs locally advanced cancers | p= 0.044 | Urine | 21788966 |
696 | EZH2 | mRNA | Humans | Upregulated in locally advanced cancers | Prognostic | localized Vs locally advanced cancers | p= 0.022 | Urine | 21788966 |
697 | EZH2 | mRNA | Humans | Upregulated in Intermediate and further upregulated in High Risk Group | Prognostic | Low Vs Intermediate Vs High Risk Group | High vs low-risk group patients (P = 0.002), intermediate vs low risk group patients (P = 0.044) | Urine | 21788966 |
698 | PCAT-1 | ncRNA | Humans | Upregulated in a subset of metastatic and high-grade localized (Gleason score ≥7) cancers | Prognostic | High grade tumor vs. low grade tumor/non-tumor | NA | Tissue | 21804560 |
705 | PCA3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Controls | NA | Blood | 21832279 |
760 | OPNa (osteopontin -a ) | mRNA | Humans | Upregulated in Cancerous Conditions (PCA: Median: 62.43; BPH: Median: 0.20) | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.05 | Tissue | 21963599 |
761 | OPNb (osteopontin -b ) | mRNA | Humans | Upregulated in Cancerous Conditions (PCA: Median: 43.47; BPH: Median: 0.50) | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.05 | Tissue | 21963599 |
762 | OPNc (osteopontin -c ) | mRNA | Humans | Upregulated in Cancerous Conditions (PCA: Median: 200.36; BPH: Median: 0.0) | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.05 | Tissue | 21963599 |
763 | tPSA | mRNA | Humans | Upregulated in Cancerous Conditions (PCA: Median: 7.51; BPH: Median: 4.15) | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.05 | Serum | 21963599 |
764 | OPNa+OPNb+OPNc | mRNA | Humans | Upregulated in Cancerous Conditions | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.05 | Tissue | 21963599 |
765 | OPNa+OPNb+OPNc+PSA | mRNA | Humans | Upregulated in Cancerous Conditions | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.05 | Tissue | 21963599 |
766 | OPNc+PSA | mRNA | Humans | Upregulated in Cancerous Conditions | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.05 | Tissue | 21963599 |
767 | OPNa (osteopontin -a ) | mRNA | Humans | Upregulated with high Gleason Score (Median for GS< 7: 0.35, Median for GS ≥ 7: 84.54) | Prognostic | Gleason Score <7 Vs Gleason Score ≥ 7 | p= 0.006 | Tissue | 21963599 |
768 | OPNb (osteopontin -b ) | mRNA | Humans | Upregulated with high Gleason Score (Median for GS< 7: 3.54, Median for GS ≥ 7: 61.19) | Prognostic | Gleason Score <7 Vs Gleason Score ≥ 7 | p = 0.003 | Tissue | 21963599 |
769 | OPNa (osteopontin -a ) | mRNA | Humans | Upregulated with high Gleason Score (Median for GS< 7: 112.06, Median for GS ≥ 7: 526.39) | Prognostic | Gleason Score <7 Vs Gleason Score ≥ 7 | p= 0.001 | Tissue | 21963599 |
786 | AMACR+CSTA+HPN+MYO6+LAMB3+ABCC4 | mRNA | Humans | Upregulated: [ABCC4, AMACR, HPN and MYO6]; Downregulated: [CSTA and LAMB3] | Diagnostic | Tumor Vs Normal Tissues | p<0.001 | Tissue | 22009027 |
800 | PRKAR1A; LRRN3; PCDH17; TTN; LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1;DEFA1; DEFA1; DEFA3; DEFA1; DEFA1; CTSG; DEFA4; ELA2; | mRNA | Humans | Downregulated (0.6-0.82 fold): [PRKAR1A; LRRN3; PCDH17; TTN;] ; Upregulated (0.6 - 1.36 fold): [LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1e;DEFA1e; DEFA1e; DEFA3; DEFA1e; DEFA1e; CTSG; DEFA4; ELA2;] | Prognostic | Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination | p< 0.008 | Blood | 22071976 |
801 | LTB; OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCA; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCA; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1; CAMP; ELA2; DEFA4; DEFA3; DEFA1; DEFA1; DEFA1; DEFA1; | mRNA | Humans | Downregulated: [LTB (1.03 fold)] ; Upregulated (1.04- 2.87 fold): [OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCAe; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCAe; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1e; CAMP; ELA2; DEFA4; DEFA3; DEFA1e; DEFA1e; DEFA1e; DEFA1e;] | Prognostic | Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - Postvaccination | p< 0.008 | Blood | 22071976 |
802 | RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; SNCA; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; ALAS2; CAMP; LCN2; OLFM4; DEFA3; DEFA1; DEFA1; DEFA1; ERAF; CA1; HBD; DEFA1; | mRNA | Humans | Upregulated Postvaccine treatment: [RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; CAMP; LCN2; OLFM4; DEFA3; DEFA1;ERAF; CA1; HBD;] | Predictive | Short Term Survival Pre Vs Post Vaccination | p< 0.008 | Blood | 22071976 |
803 | LRRN3+PCDH17+HIST1H4C+PGLYRP1 | mRNA | Humans | Downregulated: [LRRN3; PCDH17;] ; Upregulated: [HIST1H4C; PGLYRP1;] | Prognostic | Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination | p< 0.008 | Blood | 22071976 |
813 | TGFβ1 (transforming growth factor beta 1) | mRNA | Humans | Associated with Prostate cancer specific Survival | Prognostic | disease specific survival Vs no survival | p=0.0 | Tissue | 22113713 |
814 | (IL-7) Interleukin-7 | mRNA | Humans | Associated with Prostate cancer specific Survival | Prognostic | disease specific survival Vs no survival | p=0.03 | Tissue | 22113713 |
816 | ARHI | mRNA | Humans | Downregulated in aggressive Prostate Cancer (Aggressive:9.6 ± 1.2; Non Agressive: 8.3 ± 2.3 ) | Prognostic | Agressive Vs Non - Agressive Prostate Cancer | p=0.001 | Tissue | 22117988 |
822 | TDRD1 | mRNA | Humans | Upregulated in Prostate cancer | Diagnostic | Benign Vs Tumor | p<0.05 | Tissue | 22142399 |
823 | TDRD1 | mRNA | Humans | Upregulated in TMPRSS2-ERG gene fusion (36 fold) compared to benign samples and TMPRSS2-ERG gene fusion compared to non fusion (23 fold). | Prognostic | Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion | TMPRSS2-ERG positive tumors compared to normal (p = 1.77*10^-9) and fusion-negative samples (p = 1.51*10^-9) | Tissue | 22142399 |
824 | CRISP3 | mRNA | Humans | Upregulated in Prostate cancer | Diagnostic | Benign Vs Tumor | p<0.05 | Tissue | 22142399 |
825 | CRISP3 | mRNA | Humans | Upregulated in TMPRSS2-ERG gene fusion (37 fold) compared to benign samples, normal and fusion-negative tumor samples (FC = 1.2) | Diagnostic | Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion | TMPRSS2-ERG positive tumors compared to normal tissue (p = 2.2*10-12), normal and fusion-negative tumor samples (p = 0.03) | Tissue | 22142399 |
826 | CRISP3, AMACR , OR51E2, SPRR2F , TDRD1, F5, ACSM1, C20orf74, GOLM1 , MYC, CACNA1D, SFRP4, TRIB1, GDF15, LRRN1, FOLH1 , PRR16, LUZP2, RRM2, ERG, COL1A1, DNAH5, ZNF417 , SPON2, RICS, HIPK2 , ACACA , TUG1, COQ6 , LARP1, NETO2, FLJ20184, FASN, NEDD4L, LOC286161, MAOA, XPO6, ABCC4, RAB3B, TMEM45B, IMPDH2, DAPK1, LOC100131821 , C19orf48, KIAA1244 , GPI , HIVEP1, NAALADL2, C11orf92, THBS4, MYO6, BAMBI, ZNF462, SPOCK1, REPS2, SGEF, TBC1D16, TRIM36, LBH, AGPAT3, CAMKK2, GCNT1, F2R, BAT2L , LRIG1, GLYATL1 , DDX21, PLA1A, TMEFF2, SLC7A1, KIAA0368, PCDHB13 , UGT2B10 , EEF2 , C10orf137 , MICAL2, BGN, BICC1 , EIF4A1 , STX19, CHD6, ASPN, PTPN13, RAB3IP, ZNF146, BCOR, SH3RF1, TMTC4, ZDHHC9, MS4A8B, UTRN, DIP2B, UAP1, C4A , HDLBP, KIF5C, PMEPA1, GRPR , ZNF217, HUWE1, ZNF417 , AAK1 , CCDC6, BRD2, CRKRS, TP53INP1, ABCA1 , H2BFS , LIG3, PHF12, FAM117B, MED13L, TMEM2, PLA2G7, DICER1, SRRM2, BAGE2 , USP54, MYH10, SLC36A1, SLC7A11, LOC651907 , CREB3L1, ATP13A5 , ATP2B1, ANKRD34B, BAZ2A, C10orf12, POSTN, CALR3 , ZNF828, CS, ERGIC1, BXDC1, EIF4G1, PRKCSH, ABHD2, SIM2, NUFIP2, SPP1, RPL9P11 , HSN2 , JAG1, TPX2, MOSC1, TMEM161B , C4orf18 , BAT2L, DDAH1, NOLC1, ANKRD17, LOC100130958 , CMTM4, APOF, GALNT7, SETD5, HIST1H3B, TSPAN13, EPCAM, MLL, ADAR, EGR1, DNAJC10, MLEC, SEL1L, HYOU1, COL1A2, PSD3, MYO10 , ENC1 , BAT2D1, DDI2 , KDM2A , ENO1, C20orf191 , EP300, ALDH1A3, FAM119A , SLC27A2, C9orf91, TKT, NCL , ABHD2, STK33, ACTG2, IGJ, SLC26A4, SLC39A2, ZNF701 , COCH , BZW1 , CCDC68, PTPLA, VSNL1, GCNT2 , RND3, SCN7A, CYP27A1, CYP3A5 , GJA1, GSTM3, CFL2, C2 , HBB, SPATA6, KRT23, GPR87, MPPED2, HIST1H4C, OGN, LRCH2, C12orf75, NTN4, LOC100188947 , NEFH, SRD5A2, ADAM32, DPT, AZGP1, ACSS3, SLC15A2, PROM1, CACNA2D1, CXCL13, MME, ZNF483, L3MBTL4, APLF , CHRDL1, HIST1H1A, LEPREL1, ARMCX1, ANGPT1, MT1M , DSC3, B3GALT2, SLC22A3, ANO5, MT1G, PCP4, ANXA1 , PLN, EAF2 , ANPEP, TCEAL2 , LTF, PRDM5, LOC100134430 , ATRNL1, KRT15, SPOCK3, PI15, CD177, GDEP, CD38, FLRT3, SLC18A2, AOX1, MSMB, TGM4, OLFM4, SLC14A1, AMY1A | mRNA | Humans | Differentially expressed (Log fold change) [CRISP3 ( 2.93 fold); , AMACR ( 2.85 fold); , OR51E2 ( 2.46 fold); , SPRR2F ( 2.36 fold); , TDRD1 ( 2.31 fold); , F5 ( 2.23 fold); , ACSM1 ( 2.23 fold); , C20orf74 ( 2.05 fold); , GOLM1 ( 2.01 fold); , MYC ( 1.83 fold); , CACNA1D ( 1.73 fold); , SFRP4 ( 1.68 fold); , TRIB1 ( 1.68 fold); , GDF15 ( 1.67 fold); , LRRN1 ( 1.67 fold); , FOLH1 ( 1.66 fold); , PRR16 ( 1.59 fold); , LUZP2 ( 1.58 fold); , RRM2 ( 1.57 fold); , ERG ( 1.57 fold); , COL1A1 ( 1.57 fold); , DNAH5 ( 1.57 fold); , ZNF417 ( 1.56 fold); , SPON2 ( 1.56 fold); , RICS ( 1.55 fold); , HIPK2 ( 1.54 fold); , ACACA ( 1.54 fold); , TUG1 ( 1.51 fold); , COQ6 ( 1.5 fold); , LARP1 ( 1.49 fold); , NETO2 ( 1.49 fold); , FLJ20184 ( 1.48 fold); , FASN ( 1.48 fold); , NEDD4L ( 1.47 fold); , LOC286161 ( 1.46 fold); , MAOA ( 1.45 fold); , XPO6 ( 1.43 fold); , ABCC4 ( 1.43 fold); , RAB3B ( 1.42 fold); , TMEM45B ( 1.42 fold); , IMPDH2 ( 1.39 fold); , DAPK1 ( 1.38 fold); , LOC100131821 ( 1.38 fold); , C19orf48 ( 1.37 fold); , KIAA1244 ( 1.36 fold); , GPI ( 1.35 fold); , HIVEP1 ( 1.34 fold); , NAALADL2 ( 1.34 fold); , C11orf92 ( 1.34 fold); , THBS4 ( 1.33 fold); , MYO6 ( 1.31 fold); , BAMBI ( 1.31 fold); , ZNF462 ( 1.3 fold); , SPOCK1 ( 1.3 fold); , REPS2 ( 1.28 fold); , SGEF ( 1.28 fold); , TBC1D16 ( 1.27 fold); , TRIM36 ( 1.27 fold); , LBH ( 1.26 fold); , AGPAT3 ( 1.26 fold); , CAMKK2 ( 1.25 fold); , GCNT1 ( 1.24 fold); , F2R ( 1.24 fold); , BAT2L ( 1.24 fold); , LRIG1 ( 1.23 fold); , GLYATL1 ( 1.23 fold); , DDX21 ( 1.23 fold); , PLA1A ( 1.22 fold); , TMEFF2 ( 1.22 fold); , SLC7A1 ( 1.22 fold); , KIAA0368 ( 1.22 fold); , PCDHB13 ( 1.21 fold); , UGT2B10 ( 1.21 fold); , EEF2 ( 1.2 fold); , C10orf137 ( 1.2 fold); , MICAL2 ( 1.2 fold); , BGN ( 1.19 fold); , BICC1 ( 1.19 fold); , EIF4A1 ( 1.19 fold); , STX19 ( 1.18 fold); , CHD6 ( 1.18 fold); , ASPN ( 1.18 fold); , PTPN13 ( 1.18 fold); , RAB3IP ( 1.18 fold); , ZNF146 ( 1.18 fold); , BCOR ( 1.17 fold); , SH3RF1 ( 1.17 fold); , TMTC4 ( 1.16 fold); , ZDHHC9 ( 1.16 fold); , MS4A8B ( 1.16 fold); , UTRN ( 1.16 fold); , DIP2B ( 1.15 fold); , UAP1 ( 1.15 fold); , C4A ( 1.15 fold); , HDLBP ( 1.15 fold); , KIF5C ( 1.14 fold); , PMEPA1 ( 1.14 fold); , GRPR ( 1.14 fold); , ZNF217 ( 1.13 fold); , HUWE1 ( 1.13 fold); , ZNF417 ( 1.13 fold); , AAK1 ( 1.13 fold); , CCDC6 ( 1.12 fold); , BRD2 ( 1.12 fold); , CRKRS ( 1.12 fold); , TP53INP1 ( 1.12 fold); , ABCA1 ( 1.12 fold); , H2BFS ( 1.12 fold); , LIG3 ( 1.11 fold); , PHF12 ( 1.11 fold); , FAM117B ( 1.11 fold); , MED13L ( 1.11 fold); , TMEM2 ( 1.11 fold); , PLA2G7 ( 1.11 fold); , DICER1 ( 1.11 fold); , SRRM2 ( 1.1 fold); , BAGE2 ( 1.1 fold); , USP54 ( 1.1 fold); , MYH10 ( 1.1 fold); , SLC36A1 ( 1.1 fold); , SLC7A11 ( 1.1 fold); , LOC651907 ( 1.1 fold); , CREB3L1 ( 1.1 fold); , ATP13A5 ( 1.09 fold); , ATP2B1 ( 1.09 fold); , ANKRD34B ( 1.09 fold); , BAZ2A ( 1.08 fold); , C10orf12 ( 1.08 fold); , POSTN ( 1.08 fold); , CALR3 ( 1.07 fold); , ZNF828 ( 1.07 fold); , CS ( 1.07 fold); , ERGIC1 ( 1.07 fold); , BXDC1 ( 1.07 fold); , EIF4G1 ( 1.06 fold); , PRKCSH ( 1.06 fold); , ABHD2 ( 1.06 fold); , SIM2 ( 1.06 fold); , NUFIP2 ( 1.06 fold); , SPP1 ( 1.06 fold); , RPL9P11 ( 1.06 fold); , HSN2 ( 1.05 fold); , JAG1 ( 1.05 fold); , TPX2 ( 1.05 fold); , MOSC1 ( 1.04 fold); , TMEM161B ( 1.04 fold); , C4orf18 ( 1.04 fold); , BAT2L ( 1.04 fold); , DDAH1 ( 1.04 fold); , NOLC1 ( 1.03 fold); , ANKRD17 ( 1.03 fold); , LOC100130958 ( 1.03 fold); , CMTM4 ( 1.03 fold); , APOF ( 1.03 fold); , GALNT7 ( 1.02 fold); , SETD5 ( 1.02 fold); , HIST1H3B ( 1.02 fold); , TSPAN13 ( 1.02 fold); , EPCAM ( 1.02 fold); , MLL ( 1.02 fold); , ADAR ( 1.02 fold); , EGR1 ( 1.02 fold); , DNAJC10 ( 1.02 fold); , MLEC ( 1.02 fold); , SEL1L ( 1.01 fold); , HYOU1 ( 1.01 fold); , COL1A2 ( 1.01 fold); , PSD3 ( 1.01 fold); , MYO10 ( 1.01 fold); , ENC1 ( 1.01 fold); , BAT2D1 ( 1.01 fold); , DDI2 ( 1.01 fold); , KDM2A ( 1.01 fold); , ENO1 ( 1.01 fold); , C20orf191 ( 1.01 fold); , EP300 ( 1.01 fold); , ALDH1A3 ( 1.01 fold); , FAM119A ( 1.01 fold); , SLC27A2 ( 1.0 fold); , C9orf91 ( 1.0 fold); , TKT ( 1.0 fold); , NCL ( 1.0 fold); , ABHD2 ( 1.0 fold); , STK33 ( -1.0 fold); , ACTG2 ( -1.01 fold); , IGJ ( -1.01 fold); , SLC26A4 ( -1.01 fold); , SLC39A2 ( -1.01 fold); , ZNF701 ( -1.01 fold); , COCH ( -1.02 fold); , BZW1 ( -1.03 fold); , CCDC68 ( -1.03 fold); , PTPLA ( -1.04 fold); , VSNL1 ( -1.04 fold); , GCNT2 ( -1.05 fold); , RND3 ( -1.05 fold); , SCN7A ( -1.05 fold); , CYP27A1 ( -1.05 fold); , CYP3A5 ( -1.05 fold); , GJA1 ( -1.06 fold); , GSTM3 ( -1.07 fold); , CFL2 ( -1.09 fold); , C2 ( -1.09 fold); , HBB ( -1.1 fold); , SPATA6 ( -1.1 fold); , KRT23 ( -1.11 fold); , GPR87 ( -1.11 fold); , MPPED2 ( -1.11 fold); , HIST1H4C ( -1.11 fold); , OGN ( -1.12 fold); , LRCH2 ( -1.12 fold); , C12orf75 ( -1.12 fold); , NTN4 ( -1.12 fold); , LOC100188947 ( -1.12 fold); , NEFH ( -1.13 fold); , SRD5A2 ( -1.15 fold); , ADAM32 ( -1.16 fold); , DPT ( -1.16 fold); , AZGP1 ( -1.16 fold); , ACSS3 ( -1.17 fold); , SLC15A2 ( -1.17 fold); , PROM1 ( -1.18 fold); , CACNA2D1 ( -1.18 fold); , CXCL13 ( -1.18 fold); , MME ( -1.18 fold); , ZNF483 ( -1.19 fold); , L3MBTL4 ( -1.19 fold); , APLF ( -1.21 fold); , CHRDL1 ( -1.21 fold); , HIST1H1A ( -1.23 fold); , LEPREL1 ( -1.25 fold); , ARMCX1 ( -1.25 fold); , ANGPT1 ( -1.26 fold); , MT1M ( -1.27 fold); , DSC3 ( -1.29 fold); , B3GALT2 ( -1.29 fold); , SLC22A3 ( -1.3 fold); , ANO5 ( -1.31 fold); , MT1G ( -1.31 fold); , PCP4 ( -1.32 fold); , ANXA1 ( -1.32 fold); , PLN ( -1.32 fold); , EAF2 ( -1.33 fold); , ANPEP ( -1.35 fold); , TCEAL2 ( -1.39 fold); , LTF ( -1.4 fold); , PRDM5 ( -1.42 fold); , LOC100134430 ( -1.42 fold); , ATRNL1 ( -1.42 fold); , KRT15 ( -1.43 fold); , SPOCK3 ( -1.44 fold); , PI15 ( -1.44 fold); , CD177 ( -1.46 fold); , GDEP ( -1.47 fold); , CD38 ( -1.53 fold); , FLRT3 ( -1.58 fold); , SLC18A2 ( -1.69 fold); , AOX1 ( -1.72 fold); , MSMB ( -1.74 fold); , TGM4 ( -1.76 fold); , OLFM4 ( -1.85 fold); , SLC14A1 ( -1.95 fold); , AMY1A ( -2.11 fold)] | Diagnostic | Benign Vs Tumor | p<0.006857824 | Tissue | 22142399 |
833 | APOD; C1QTNF3; CD27; CFB; CFH; CLU; CRABP1; DDAH2; FTL; IGSF8; ITIH4l; LGALS3; LYZ; MGAT5; PECAM1; RBP4; RECK; SELENBP1; SLIT2; | mRNA | Humans | (1.358 fold) Upregulated in PCa [APOD (2.803 fold) ; C1QTNF3 (1.100 fold); CD27 (1.183 fold); CFB (3.231 fold); CFH (1.381 fold); CLU (1.638 fold); CRABP1 (1.477 fold) ; DDAH2 (1.152 fold) ; FTL (1.718 fold); IGSF8 (1.358 fold) ; ITIH4l (1.215 fold) ; LGALS3 (4.121 fold) ; LYZ (2.093 fold) ; MGAT5 (1.112 fold); PECAM1 (2.404 fold) ; RBP4 (1.872 fold); RECK (2.569 fold) ; SELENBP1 (1.327 fold) ; SLIT2 (1.848 fold)] | Diagnostic | Prostate Cancer Vs Normal controls | p<0.001 | Urine | 22194848 |
882 | ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1 | LncRNA | Humans | Differentially expressed (Median Fold Change): [ANRIL (MFD: −1.17 fold); H19 (MFD: 1.32 fold); PCA3 (MFD: 14.3 fold); MALAT1 (MFD: −1.64 fold); PCGEM1 (MFD: 1.75 fold); PTENP1 (MFD: −1.34 fold);] | Diagnostic | Primary Vs Normal | p<0.01 | Tissue | 22371711 |
883 | ANRIL; H19; PCA3; MALAT1 | LncRNA | Humans | Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.49 fold); H19 (MFD: 1.43 fold); PCA3 (MFD: 4.46 fold); MALAT1 (MFD: -3.33 fold)] | Diagnostic | Metastatic Vs Normal | p<0.01 | Tissue | 22371711 |
884 | ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1 | LncRNA | Humans | Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.33 fold); H19 (MFD: -1.12 fold); PCA3 (MFD: -3.44 fold); MALAT1 (MFD: -2.63 fold); PCGEM1 (MFD: -4 fold); PTENP1 (MFD: 1.50 fold);] | Diagnostic | Metastatic Vs Primary | p<0.04 | Tissue | 22371711 |
887 | kallikrein-related peptide 4 (KLK4) | mRNA | Humans | Downregulated in genistein treated patients compared to placebo treated | Predictive | Treated with Placebo Vs Treated with Genistein (30mg capsule) | p=0.033 | Tissue | 22397815 |
896 | Ring finger protein 19A (RNF19A) | mRNA | Humans | Upregulated in PCa (>2 fold) | Diagnostic | Prostate Cancer vs healthy controls | p = 0.0066 | Blood | 22493721 |
903 | ERG | mRNA | Humans | Upregulated in TMPRSS2-ERG positive fusion cases | Prognostic | TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer | p<0.0001 | Tissue | 22505341 |
904 | SPINK1 | mRNA | Humans | Upregulated in TMPRSS2-ERG negative fusion cases | Prognostic | TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer | p=0.03 | Tissue | 22505341 |
905 | ERG | mRNA | Humans | Upregulated in TERT positive cases | Prognostic | TERT positive compared to TERT negative in Prostate cancer | p=0.016 | Tissue | 22505341 |
906 | Fusion status of TMPRSS2-ERG and TERT expression | mRNA | Humans | TMPRSS2–ERG and TERT-negative tumors had significantly lower rate of recurrence | Prognostic | Biochemical Recurrence Free Survival | p=0.025 | Urine | 22505341 |
918 | PCA3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs No Cancer (@ first negative biopsy) [Group A] | NA | Urine | 22564540 |
919 | PCA3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs No Cancer (@ first negative biopsy) [Group B] | NA | Urine | 22564540 |
934 | NACA + CCNB1 | mRNA | Humans | CCNB1 upregulated in Prostate cancer; NACA Downregulated in Prostate Cancer | Diagnostic | BPC VS BP | p<0.05 | Tissue | 22640805 |
935 | GPR37; SOX4; CCNB1; TOP2A; DLG5; NACA; NR2C2; PDCD5; IDSP1 | mRNA | Humans | Upregulated: [GPR37; SOX4; CCNB1; TOP2A;] Downregulated: [DLG5; NACA; NR2C2; PDCD5; IDSP1] | Diagnostic | BPC (benign prostates containing PCa) VS BP | GPR37 (training: 0.018, testing: 0.003); SOX4 (training: 0.03, testing: 0.03); CCNB1 (training: 0.002, testing: 0.007); TOP2A (training: 0.018); DLG5 (training: p< 0.001, testing: 0.004); NACA (p<0.001, testing: 0.003) ; NR2C2 (training: p<0.001, testing: 0.02); PDCD5 (training: p<0.001); IDSP1 (training: p<0.001) | Tissue | 22640805 |
936 | PCA3 | mRNA | Humans | Upregulated (RQ = NP: 7.4 Vs LG = 202) | Diagnostic | Normal adjacent to Prostate (NP) Vs Low Grade PCa | <0.005 | Tissue | 22674214 |
937 | TMPRSS2:ERG Fusion | mRNA | Humans | Upregulated (RQ = NP: 0.6 Vs LG = 11) | Diagnostic | Normal adjacent to Prostate (NP) Vs Low Grade PCa | <0.005 | Tissue | 22674214 |
938 | PCA3 + TMPRSS2:ERG gene fusion | mRNA | Humans | Upregulated in PCa | Diagnostic | Normal adjacent to Prostate (NP) Vs Low Grade PCa | NA | Tissue | 22674214 |
939 | TMPRSS2:ERG gene fusion (given that PCA3 test is negative) | mRNA | Humans | Upregulated in PCa | Diagnostic | Normal adjacent to Prostate (NP) Vs Low Grade PCa | NA | Tissue | 22674214 |
962 | Prostate Cancer Antigen 3 (PCA3) | mRNA | Humans | Upregulated in PCa [No PCa: 32 (13.5–68) Vs PCa 50 (34–83)] | Diagnostic | PCa Vs No-PCa | p=0.001 | Urine | 22821756 |
963 | PCA3 + phi | mRNA | Humans | Upregulated in PCa | Diagnostic | PCa Vs No-PCa | p=0.001 | Urine + Serum | 22821756 |
968 | GADD45B; CDKN1A; NLRP1; ERBB3; FMO5; SERINC2; AMFR; DPP4; PGC; YWHAE; EHF; TF; TNFSF10; EIF5A; TGM4; | mRNA | Humans | Upregulated in Relapse: [GADD45B (4.86 fold); CDKN1A (2.65 fold); NLRP1 (1.57 fold)]; Downregulated in Relapse: [ERBB3 (0.55 fold); FMO5 (0.55 fold); SERINC2 (0.43 fold); AMFR (0.41 fold); DPP4 (0.40 fold); PGC (0.38 fold); YWHAE (0.34 fold); EHF(0.33 fold); TF (0.33 fold); TNFSF10 (0.31 fold); EIF5A (0.15 fold); TGM4 (0.03 fold);] | Prognostic | Relpase Vs No Relapse | p<0.05 | Tissue | 22870216 |
978 | ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; | genes or ncRNA | Humans | Upregulated: AOX1-001, RSRC2-017, ABCC4-004, ALK-001, ATP1A1-002, NAMPT-006, RP11-627G23.1-004 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.0 | Diagnostic | Primary Vs Normal | p<0.05 | Tissue | 22956952 |
979 | ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; | genes or ncRNA | Humans | Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1 | Prognostic | Metastatic Vs Primary | p<0.05 | Tissue | 22956952 |
980 | ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; | genes or ncRNA | Humans | Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1 | Diagnostic | Metastatic Vs Normal | p<0.05 | Tissue | 22956952 |
981 | ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; | genes or ncRNA | Humans | NA | Prognostic | Biochemical Recurrence | p<0.005 | Tissue | 22956952 |
983 | EGFR | mRNA | Humans | Overexpressed for Progression Free Survival | Prognostic | Progression Free Survival | p= 0.005 | Tissue | 22977195 |
985 | PTEN | mRNA | Humans | Overexpressed for Progression Free Survival | Prognostic | Progression Free Survival | p= 0.0003 | Tissue | 22977195 |
986 | PTEN | mRNA | Humans | Overexpressed for Progression Free Survival | Prognostic | Overall Survival | p= 0.02 | Tissue | 22977195 |
987 | EGFR + PTEN | mRNA | Humans | Overexpressed for Progression Free Survival | Prognostic | Progression Free Survival | NA | Tissue | 22977195 |
994 | Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) | mRNA | Humans | Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)] | Prognostic | Biochemical relapse Vs No biochemical Relpase | p<0.002 | Tissue | 23028830 |
995 | Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) + Cell Type Hetrogenity + Gleason Score | mRNA | Humans | Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)] | Prognostic | Biochemical relapse Vs No biochemical Relpase | p<0.002 | Tissue | 23028830 |
996 | GPX1 | mRNA | Humans | Upregulated in Metatstasis | Prognostic | Relpase Vs No Relapse | p<0.001 | Blood | 23046102 |
997 | SOD2 | mRNA | Humans | Upregulated in Metatstasis | Prognostic | Relpase Vs No Relapse | p=0.01 | Blood | 23046102 |
998 | AR | mRNA | Humans | Differentially Expressed | Prognostic | Relpase Vs No Relapse | p=0.001 | Blood | 23046102 |
999 | Cyclin B | mRNA | Humans | Differentially Expressed | Prognostic | Relpase Vs No Relapse | p=0.007 | Blood | 23046102 |
1000 | bFGF | mRNA | Humans | Differentially Expressed | Prognostic | Relpase Vs No Relapse | p=0.004 | Blood | 23046102 |
1001 | 2 or more out of (GPX1; SOD2; AR; Cyclin B; bFGF) | mRNA | Humans | Differentially Expressed | Prognostic | Relpase Vs No Relapse | p<0.001 | Blood | 23046102 |
1002 | ABL2+SEMA4D+ITGAL+C1QA+TIMP1+CDKN1A | mRNA | Humans | NA | Prognostic | low-risk group Vs high-risk group | p<0.05 | Blood | 23059047 |
1003 | CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) | mRNA | Humans | Downregulated (1.58 fold) | Diagnostic | Controls Vs High Grade Prostate Cancer (GS 8 and above) | p = 0.0000346 | Blood | 23071848 |
1004 | CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) | mRNA | Humans | Downregulated (1.59 fold) | Diagnostic | Controls Vs High Grade Prostate Cancer (GS 8 and above) | p=0.0000338 | Blood | 23071848 |
1005 | FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) | mRNA | Humans | Downregulated (1.61 fold) | Diagnostic | Controls Vs High Grade Prostate Cancer (GS 8 and above) | p = 0.00000285 | Blood | 23071848 |
1006 | KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) | mRNA | Humans | Downregulated (1.44 fold) | Diagnostic | Controls Vs High Grade Prostate Cancer (GS 8 and above) | p = 0.000000182 | Blood | 23071848 |
1007 | KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) | mRNA | Humans | Downregulated (1.66 fold) | Diagnostic | Controls Vs High Grade Prostate Cancer (GS 8 and above) | p=0.000000816 | Blood | 23071848 |
1008 | TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) | mRNA | Humans | Downregulated (1.52 fold) | Diagnostic | Controls Vs High Grade Prostate Cancer (GS 8 and above) | p = 0.000084 | Blood | 23071848 |
1009 | Combination of 6 genes duplexes [CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] | mRNA | Humans | Downregulated (1.52 fold) | Diagnostic | Controls Vs High Grade Prostate Cancer (GS 8 and above) | p = 0.000084 | Blood | 23071848 |
1010 | PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3) + KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) | mRNA | Humans | Downregulated (1.52 fold) | Diagnostic | Controls Vs High Grade Prostate Cancer (GS 8 and above) | p = 0.000084 | Blood | 23071848 |
1011 | PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3)+ KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) | mRNA | Humans | Downregulated (1.52 fold) | Diagnostic | Controls Vs High Grade Prostate Cancer (GS 8 and above) | p = 0.000084 | Blood | 23071848 |
1020 | PCA3 score >= 25 | mRNA | Humans | PCA3 Score upregulated in PCa (No PCa: 24; Pca: 60) | Diagnostic | PCa Vs No PCA group | p<0.001 | Urine | 23201468 |
1021 | TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene homolog) >= 10 | mRNA | Humans | TMPRSS2-ERG fusion upregulated in PCa (No PCa: 15; Pca: 46) | Diagnostic | PCa Vs No PCA group | p<0.001 | Urine | 23201468 |
1022 | TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene homolog) >= 10 | mRNA | Humans | NA | Prognostic | Gleason Score <7 Vs Gleason score ≥ 7 | p<0.001 | Urine | 23201468 |
1023 | TMPRSS2-ERG | mRNA | Humans | NA | Prognostic | Tumor Stage (T3-T4) | p = 0.023 | Urine | 23201468 |
1042 | Early Growth Response 3 (Egr3) | mRNA | Humans | Upregulated in PCa (5.35 fold) | Diagnostic | Prostate Cancer Vs Normal Prostate | p = 2 x 10^-15 | Tissue | 23342084 |
1045 | Early Growth Response 1 (Egr1) | mRNA | Humans | Downregulated in Relapse (0.784 fold) | Prognostic | Relpase Vs No Relapse | p = 0.017 | Tissue | 23342084 |
1065 | PCA3 | mRNA | Humans | Upregulated in Cancerous Conditions (Cancerous: 7.69 Vs Non Cancerous: 7.00) | Diagnostic | Cancerous Vs Non Cancerous | p<0.0005 | Tissue | 23391636 |
1066 | PCA3 | mRNA | Humans | Upregulated in Stage pT3/4 (1.9 Median fold difference) | Diagnostic | Stage pT2 Vs Stage pT3/4 | p=0.015 | Tissue | 23391636 |
1067 | KLK15 | mRNA | Humans | Upregulated in Stage pT3/4 (2.71 Median fold difference) | Diagnostic | Stage pT2 Vs Stage pT3/4 | p=0.032 | Tissue | 23391636 |
1079 | PCA3 | mRNA | Humans | Upregulated with High Gleason Score | Prognostic | Low Gleason Score Vs high Gleason Score (≥7) | p=0.02 | Urine | 23515404 |
1080 | TMPRSS2:ERG | mRNA | Humans | Upregulated with High Gleason Score | Prognostic | Low Gleason Score Vs high Gleason Score (≥7) | p=0.02 | Urine | 23515404 |
1081 | PCA3 + TMPRSS2:ERG | mRNA | Humans | Upregulated with High Gleason Score | Prognostic | Low Gleason Score Vs high Gleason Score (≥7) | NA | Urine | 23515404 |
1082 | PCA3 | mRNA | Humans | Upregulated in Positive Biopsy | Diagnostic | Positive Vs Negative Biopsy | P =0.01 | Urine | 23515404 |
1083 | TMPRSS2:ERG | mRNA | Humans | Upregulated in Positive Biopsy | Diagnostic | Positive Vs Negative Biopsy | P =0.001 | Urine | 23515404 |
1084 | PCA3 + TMPRSS2:ERG + PSA | mRNA | Humans | Upregulated with High Gleason Score | Prognostic | Low Gleason Score Vs high Gleason Score (≥7) | NA | Urine | 23515404 |
1126 | PCA3; GAS5; PVT1; DANCR; PCAT1; MEG3; PRINS; HOTTIP; EGOT; | LncRNA | Humans | Upregulated in PCa: [PCA3; GAS5; PVT1; DANCR; PCAT1;]lDownregulated in PCa: [MEG3; PRINS; HOTTIP; EGOT;] | Diagnostic | Tumor Vs Normal Tissues | p< 0.05 | Tissue | 23728290 |
1144 | HPN; CLDN3; AMACR; GOLPH2; TRIB1; LOC729677; GDF15; TARP; MYC; LOC731404; ZFP36; SIM2; CTGF; GJB1; CENPN; EGR2; FBP1; KLF4; LUZP2; C8orf4; PDLIM3; CREB3L1; GCNT1; CTPS; PTP4A3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.001 | Tissue | 23813660 |
1145 | SLC14A1; LOC642587; TRIM29; CYP3A5; TP73L; SNAI2; PIK3R1; KRT5; NPAL3; FGFR2; CSTA; CAPG; ITGA2; FER1L3; MEIS2; LGALS3BP; GPRC5B; NEFH; GSTM2; S100A16; MME; EVA1; KRT23; ADD3; GSTP1; | mRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.001 | Tissue | 23813660 |
1146 | Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;] | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | NA | Tissue | 23813660 |
1147 | Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;] | mRNA | Humans | Upregulated in PCa | Diagnostic | Agressive Vs Non Agressive Prostate Cancer | NA | Tissue | 23813660 |
1155 | LASP1 + IQGAP3+ NFIB+ S1PR4+ THBS2+ANO7+ PCDH7 + MYBPC1+ EPPK1+ TSBP+ PBX1+ NUSAP1+ ZWILCH+ UBE2C+ CAMK2N1+ RABGAP1+ PCAT-32 + GLYATL1P4/PCAT-80 + TNFRSF19 | mRNA | Humans | Differentially Expressed | Prognostic | Metastasis Vs No Metastasis | p<0.01 | Tissue | 23826159 |
1160 | Crystallin, alpha B (CRYAB) | mRNA | Humans | Downregulated in PCa | Diagnostic | Cancerous Vs non cancerous conditions | p<0.01 | Tissue | 23840433 |
1161 | Distal-less homeobox 1 (DLX1) | mRNA | Humans | Upregulated in PCa | Diagnostic | Cancerous Vs non cancerous conditions | p<0.01 | Tissue | 23840433 |
1162 | Serum deprivation response (SDPR) | mRNA | Humans | Downregulated in PCa | Diagnostic | Cancerous Vs non cancerous conditions | p<0.01 | Tissue | 23840433 |
1163 | Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 (KCNMA1) | mRNA | Humans | Downregulated in PCa | Diagnostic | Cancerous Vs non cancerous conditions | p<0.01 | Tissue | 23840433 |
1164 | Prostate Cancer Antigen 3 (PCA3) | mRNA | Humans | Upregulated in PCa | Diagnostic | Cancerous Vs non cancerous conditions | p<0.01 | Tissue | 23840433 |
1165 | Aldo-keto reductase family 1, member C1/2 (AKR1C1/2) | mRNA | Humans | Downregulated in PCa | Diagnostic | Cancerous Vs non cancerous conditions | p<0.01 | Tissue | 23840433 |
1166 | Cyclin-dependent kinase 5, regulatory subunit 1 (CDK5R1) | mRNA | Humans | Downregulated in PCa | Diagnostic | Cancerous Vs non cancerous conditions | p<0.01 | Tissue | 23840433 |
1167 | Claudin 7 (CLDN7) | mRNA | Humans | Upregulated in PCa | Diagnostic | Cancerous Vs non cancerous conditions | p<0.01 | Tissue | 23840433 |
1168 | Activated leukocyte cell adhesion molecule (ALCAM) | mRNA | Humans | Upregulated in PCa | Diagnostic | Cancerous Vs non cancerous conditions | p<0.01 | Tissue | 23840433 |
1169 | RAS, dexamethasone-induced 1 (RASD1) | mRNA | Humans | Upregulated in PCa | Diagnostic | Cancerous Vs non cancerous conditions | p<0.01 | Tissue | 23840433 |
1175 | PCA3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs No evidence of Maligancy | p <0.001 | Urine | 23861782 |
1176 | Prostate Health Index (phi) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs No evidence of Maligancy | p <0.001 | Serum | 23861782 |
1214 | PCA3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Normal Prostate | NA | Urine | 24080222 |
1216 | Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) | mRNA | Humans | Upregulated in PCa (4 fold) | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p = 0.03 | Tissue | 24081904 |
1220 | Semaphorin 4F (SF4) | mRNA | Humans | Upregulated (high levels) had increased risk of biochemical recurrence | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p = 0.0002 | Tissue | 24097862 |
1240 | Prostate cancer antigen 3 [PCA3] | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs No Prostate Cancer | NA | Urine | 24211598 |
1241 | PCA3 /PSA ratio (PCa antigen 3 [PCA3]) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs No Prostate Cancer | NA | Urine | 24211598 |
1254 | Forkhead Box A1 [FOXA1] | mRNA | Humans | Increased in shorter time to Biochemical Recurrence | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p = 0.028 | Tissue | 24292680 |
1255 | ACACA; CDCA3; CEP55; CCNB1; CKS2; DLGAP5; SLC7A1;HMMR; HIG2; LOX; MMP10; MCOLN2; NLN; PDLIM5; PSD3; C20orf74; FAM80A; SDK1; STC2; SOX4; TMEM200A; TFF3; UBE2C; UBE2E3; | mRNA | Humans | Upregulated in PCa (log 2 PCa/Normal): [] | Diagnostic | Prostate Cancer Vs Normal Prostate | NA | Tissue | 24349376 |
1256 | Discs Large Homolog 7 [DLG7] | mRNA | Humans | Upregulated in PCa (log 2 PCa/Normal): [] | Prognostic | Progression Vs No Progression | NA | Tissue | 24349376 |
1257 | Occludin | mRNA | Humans | Downregulated in: [CAHPV-10 (19.08 fold); DU145 (3.2 fold); PC-3 (4.3 fold)]; Upregulated in LNCaP: (2.2 fold) | Diagnostic | CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 | CAHPV-10 (p= 0.001); DU145 (p=0.003); PC-3 (0.003); LNCaP: (p = 0.001) | Cell Lines | 24358122 |
1258 | Claudin 1 | mRNA | Humans | Downregulated in: [CAHPV-10 (10 fold); LNCaP: (100 fold); DU145 (2.1 fold); PC-3 (3.8 fold)]; | Diagnostic | CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 | p = 0.001 | Cell Lines | 24358122 |
1259 | Claudin 7 | mRNA | Humans | Downregulated in: [DU145 (5.3 fold); PC-3 (24.8 fold)];Upregulated in LNCaP: (4.63 fold) | Diagnostic | CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 | DU145 (p=0.004); PC-3 (p= 0.01); LNCaP (p = 0.001) | Cell Lines | 24358122 |
1260 | Claudin 7 | mRNA | Humans | Downregulated in DU145 and PC-3 | Prognostic | DU145, PC-3 Vs CAHPV-10 | DU145 (p=0.02); PC-3 (p<0.001) | Cell Lines | 24358122 |
1261 | α-catenin | mRNA | Humans | Downregulated in: [DU145 (2.2 fold); PC-3 (33 fold)]; | Diagnostic | CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 | p<0.001 | Cell Lines | 24358122 |
1262 | α-catenin | mRNA | Humans | Downregulated in DU145 and PC-3 | Prognostic | DU145, PC-3 Vs CAHPV-10 | p<0.001 | Cell Lines | 24358122 |
1263 | β-catenin | mRNA | Humans | Downregulated in: [CAHPV-10 (3 fold)] ;Upregulated in [LNCaP: (3.8 fold) DU145 (2.2 fold); PC-3 (2.1 fold)] | Diagnostic | CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 | CAHPV-10 (p= 0.015); DU145 (p=0.001); PC-3 (p=0.001) LNCap: (p<0.001) | Cell Lines | 24358122 |
1264 | β-catenin | mRNA | Humans | Upregulated in DU145 and PC-3 | Prognostic | DU145, PC-3 Vs CAHPV-10 | DU145 (p=0.006); PC-3 (p=0.001) | Cell Lines | 24358122 |
1265 | E-Cadherin | mRNA | Humans | Downregulated in: [CAHPV-10 (2.3 fold) ; DU145 (5.6 fold); PC-3 (7.25 fold)] | Diagnostic | CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 | CAHPV-10 (p= 0.004); DU145 (p<0.001); PC-3 (p<0.001); | Cell Lines | 24358122 |
1288 | F3 | mRNA | Humans | NA | Prognostic | Overall Survival Vs No Survival | p=0.001 | Tissue | 24394557 |
1289 | WNT5B | mRNA | Humans | NA | Prognostic | Overall Survival Vs No Survival | p=0.004 | Tissue | 24394557 |
1290 | VGLL3 | mRNA | Humans | NA | Prognostic | Overall Survival Vs No Survival | p<0.0001 | Tissue | 24394557 |
1291 | c-MAF-a | mRNA | Humans | NA | Prognostic | Overall Survival Vs No Survival | p=0.008 | Tissue | 24394557 |
1292 | CTGF | mRNA | Humans | NA | Prognostic | Overall Survival Vs No Survival | p=0.008 | Tissue | 24394557 |
1293 | AMACR | mRNA | Humans | NA | Prognostic | Overall Survival Vs No Survival | p=0.009 | Tissue | 24394557 |
1294 | MUC1 | mRNA | Humans | NA | Prognostic | Overall Survival Vs No Survival | p=0.025 | Tissue | 24394557 |
1295 | F3 | mRNA | Humans | NA | Prognostic | PCa Specific Survival Vs No PCa Specific Survival | p<0.0001 | Tissue | 24394557 |
1296 | WNT5B | mRNA | Humans | NA | Prognostic | PCa Specific Survival Vs No PCa Specific Survival | p<0.0001 | Tissue | 24394557 |
1297 | VGLL3 | mRNA | Humans | NA | Prognostic | PCa Specific Survival Vs No PCa Specific Survival | p=0.014 | Tissue | 24394557 |
1298 | c-MAF-a | mRNA | Humans | NA | Prognostic | PCa Specific Survival Vs No PCa Specific Survival | p=0.036 | Tissue | 24394557 |
1299 | CTGF | mRNA | Humans | NA | Prognostic | PCa Specific Survival Vs No PCa Specific Survival | p=0.023 | Tissue | 24394557 |
1300 | IGFBP3 | mRNA | Humans | NA | Prognostic | PCa Specific Survival Vs No PCa Specific Survival | p=0.013 | Tissue | 24394557 |
1301 | c-MAF-b | mRNA | Humans | NA | Prognostic | PCa Specific Survival Vs No PCa Specific Survival | p=0.019 | Tissue | 24394557 |
1302 | EZH2 | mRNA | Humans | NA | Prognostic | PCa Specific Survival Vs No PCa Specific Survival | p=0.018 | Tissue | 24394557 |
1303 | AMACR | mRNA | Humans | NA | Prognostic | PCa Specific Survival Vs No PCa Specific Survival | p=0.049 | Tissue | 24394557 |
1304 | VGLL3 + IGFBP3 + F3 | mRNA | Humans | NA | Prognostic | Overall Survival Vs No Survival | Univariate: [p<0.0001;] Multivariate:[Group2: p=0.013 Group 1: p<0.0001] | Tissue | 24394557 |
1305 | Clinical Parameters + VGLL3 + IGFBP3 + F3 | mRNA | Humans | NA | Prognostic | Overall Survival Vs No Survival | NA | Tissue | 24394557 |
1306 | VGLL3 + IGFBP3 + F3 | mRNA | Humans | NA | Prognostic | PCa Specific Survival Vs No PCa Specific Survival | Group2: [Univariate: p= 0.002; Multivariate: 0.030]; Group 1: p<0.0001 | Tissue | 24394557 |
1307 | Clinical Parameters + VGLL3 + IGFBP3 + F3 | mRNA | Humans | NA | Prognostic | PCa Specific Survival Vs No PCa Specific Survival | NA | Tissue | 24394557 |
1331 | UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level | mRNA | Humans | NA | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | NA | Urine + Plasma | 24512523 |
1332 | UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level | mRNA | Humans | NA | Prognostic | Gleason Score <7 Vs Gleason Score ≥ 7 | NA | Urine + Plasma | 24512523 |
1337 | PCAT18 | LncRNA | Humans | Upregulated in PCa (8.8-11.1 fold) | Diagnostic | Prostate Cancer Vs Normal Prostate | p<0.001 | Tissue | 24519926 |
1338 | PCAT18 | LncRNA | Humans | Upregulated in metastatic Prostatic Cancer | Prognostic | Localised Vs Metastatic Prostate Cancer | p<0.001 | Tissue | 24519926 |
1381 | BTG2; CDC37L1; COL15A1; COL3A1; EIF2D; FDPS; HIST1H1C; HIST1H2BG; IFT57; IGFBP3; ITPR1; LBH; LOC284801; MARCH5; MED4; MEMO1; MXI1; PTN; RPL23AP53; SACM1L; SIRT1; SNORA20; SRSF3; SYNM; | mRNA | Humans | Poor score with decreased BCR Survival | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p = 1.45E-21; Validation: p=2.85e-3 | Tissue | 24713434 |
1395 | GABRE | mRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Non Malignant | p=0.001 | Tissue | 24737792 |
1401 | GABRE + miR-224 +miR-452 | mRNA + miRNA | Humans | Downregulated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p=0.001 | Tissue | 24737792 |
1402 | GABRE | RNA | Humans | Downregulated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p=0.001 | Tissue | 24737792 |
1405 | OAZ2 | mRNA | Humans | Downregulated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p=0.001 | Tissue | 24737792 |
1406 | GABRE + miR-224 +miR-452+OAZ2 | mRNA + miRNA | Humans | Downregulated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p=0.001 | Tissue | 24737792 |
1426 | PCA3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Negative Vs Positive Biopsy for PCa | p<0.0001 | Urine | 24803095 |
1427 | PCA3 | mRNA | Humans | Upregulated in PCa | Diagnostic | Controls Vs Positive Biopsy for PCa | p <0.0001 | Urine | 24803095 |
1522 | Oligophrenin-1 (OPHN1) | mRNA | Humans | Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) | Diagnostic | Prostate Cancer Vs Non Neoplastic Samples | NA | Tissue | 25170626 |
1539 | Anterior gradient 2 Wild Type (AGR2wt) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p<0.05 | Tissue | 25237833 |
1540 | Anterior gradient 2 Slice Variant H (AGR2-SV-H) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p<0.05 | Tissue | 25237833 |
1541 | Anterior gradient 2 Wild Type (AGR2wt) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p<0.001 | Urine | 25237833 |
1542 | Anterior gradient 2 Slice Variant C (AGR2-SV-C) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p≤0.001 | Urine | 25237833 |
1543 | Anterior gradient 2 Slice Variant E (AGR2-SV-E) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p<0.01 | Urine | 25237833 |
1544 | Anterior gradient 2 Slice Variant F (AGR2-SV-F) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p<0.01 | Urine | 25237833 |
1545 | Anterior gradient 2 Slice Variant G (AGR2-SV-G) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p≤0.001 | Urine | 25237833 |
1546 | Anterior gradient 2 Slice Variant H (AGR2-SV-H) | mRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p≤0.001 | Urine | 25237833 |
1548 | STEAP1 (Six transmembrane epithelial antigen of the prostate) | mRNA | Humans | Upregulated in Low Risk PCa (4.45 fold) | Diagnostic | Low Risk PCa Vs Normal Tissue | p = 0.007 | Tissue | 25248617 |
1549 | STEAP1 (Six transmembrane epithelial antigen of the prostate) | mRNA | Humans | Upregulated in High Risk PCa (8.15 fold) | Diagnostic | High Risk PCa Vs Normal Tissue | p=0.011 | Tissue | 25248617 |
1550 | STEAP1 (Six transmembrane epithelial antigen of the prostate) | mRNA | Humans | Upregulated in Metastatic PCa (7.45 fold) | Diagnostic | Metastatic PCa Vs Normal Tissue | p=0.011 | Tissue | 25248617 |
1551 | STEAP2 (Six transmembrane epithelial antigen of the prostate) | mRNA | Humans | Upregulated in Low Risk Localised PCa (5.77 fold) | Diagnostic | Low Risk Localised PCa Vs Normal Tissue | p=0.022 | Tissue | 25248617 |
1552 | STEAP2 (Six transmembrane epithelial antigen of the prostate) | mRNA | Humans | Upregulated in Locally Advanced PCa (14.10 fold) | Diagnostic | Localy Advanced PCa Vs Normal Tissue | p=0.003 | Tissue | 25248617 |
1564 | WISP1 | mRNA | Humans | Upregulated in Metastatic PCa | Prognostic | Primary Vs Metastatis Prostate Cancer | p=0.03 | Tissue | 31069142 |
1565 | TMEFF2 | mRNA | Humans | Upregulated in PCa (Log 2 Median Centered Intensity) | Diagnostic | Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer | p<0.05 | Tissue | 31060542 |
1566 | TMEFF2 | mRNA | Humans | Upregulated in PCa (Log 2 Median Centered Intensity) | Prognostic | Primary/Localised Vs Metastatic/CRPC Prostate Cancer | p<0.05 | Tissue | 31060542 |
1567 | TMEFF2 | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p<0.0001 | Tissue | 31060542 |
1568 | BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; | mRNA | Humans | Upregulated in PCa (Log 2 Median Centered Intensity) | Diagnostic | Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer | p<0.05 | Tissue | 31060542 |
1569 | BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 31060542 |
1570 | BUB1B+CDC45+CDK1+CENPI+CLSPN+ERCC6L+EXO1+NCAPG+NUSAP1+RAD51+RRM2 | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 31060542 |
1586 | AF087978; uc002llc; EF177379; BC013821; uc001pyz; AK024556; AB116553; BC012900; LOC100506303; LOC100506922y; LOC100287482; XLOC_l2_009441; LOC154822; XLOC_010807; XLOC_002335; XLOC_l2_009136; XLOC_002871; ANKRD20A9Py; FLJ20444; XLOC_003734y; LOC100505666; LOC100506411; XLOC_007697; XLOC_003734y; XLOC_l2_000735; LOC100129480; XLOC_007162; LOC100506802; LOC100507025; XLOC_010813; | LncRNA | Humans | Upregulated in PC3 (Log Fold Change) [AF087978 (5.8 fold) ; uc002llc(4.8 fold) ; EF177379(4.3 fold) ; BC01382(3.8 fold)1 ; uc001pyz(3.7 fold) ; AK024556 (3.7 fold) ; AB116553 (3.5 fold) ; BC012900 (3.5 fold) ; LOC100506303(2.6 fold) ; LOC100506922(3.6 fold); LOC100287482 (3.0 fold); XLOC_l2_009441 (3.3 fold); LOC154822 (3.2 fold) ; XLOC_010807(3.5 fold) ; XLOC_002335 (3.4 fold); XLOC_l2_009136(2.1 fold); XLOC_002871 (2.3 fold); ANKRD20A9P ( 2.0 fold) ; FLJ20444 (4.1 fold); XLOC_003734( 4.0 fold); LOC100505666(2.1 fold); LOC100506411(4.1 fold); XLOC_007697(3.4 fold); XLOC_003734y(3.5 fold) XLOC_l2_000735(4.6 fold); LOC100129480(4.5 fold); XLOC_007162(3.1 fold); LOC100506802(3.4 fold); LOC100507025(5.7 fold); XLOC_010813(3.8 fold;] | Diagnostic | PC3 Cells Vs prostate epithelial cells | p<0.05 | Cell Lines | 25307116 |
1587 | LOC100506303; LOC100506922; LOC100287482; XLOC_l2_009441; LOC154822; XLOC_010807; XLOC_002335; XLOC_l2_009136; XLOC_002871; ANKRD20A9Py; FLJ20444; XLOC_003734y; LOC100505666; LOC100506411; XLOC_007697; XLOC_003734y; XLOC_l2_000735; LOC100129480; XLOC_007162; LOC100506802; LOC100507025; XLOC_010813; | LncRNA | Humans | Upregulated in LNCaP (log fold change): [LOC100506303(5.1 fold); LOC100506922y(4.9 fold); LOC100287482(4.8 fold) ; XLOC_l2_009441(4.7 fold); LOC154822(4.6 fold); XLOC_010807 (4.5 fold) ; XLOC_002335( 4.5 fold) ; XLOC_l2_009136(4.4 fold) ; XLOC_002871( 4.2 fold) ; ANKRD20A9(4.0 fold); FLJ20444(4.0 fold); XLOC_003734(3.8 fold) ; LOC100505666(3.7 fold) ; LOC10050641( 3.5 fold)1; XLOC_007697(3.3 fold); XLOC_003734y(3.2 fold); XLOC_l2_000735(2.8 fold); LOC100129480(2.4 fold); XLOC_007162(2.2 fold); LOC100506802(2.1 fold) ; LOC100507025(2.1 fold) ; XLOC_010813(2.1 fold) ;] | Diagnostic | LNCaP Cells Vs prostate epithelial cells | p<0.05 | Cell Lines | 25307116 |
1588 | XLOC_001699; XLOC_005327y; LOC400958; XLOC_008559y; LINC00340; XLOC_000495; RPS18; XLOC_012294; XLOC_l2_008560; XLOC_009911y; | LncRNA | Humans | Upregulated in PCa [Log2 (Tumor/Normal)]: [XLOC_001699 (4.3 fold) ; XLOC_005327y (4.1 fold); LOC400958 (3.9 fold); XLOC_008559y (3.7 fold) ; LINC00340 (3.6 fold) ; XLOC_000495 (3.6 fold) ; RPS18(3.3 fold) ; XLOC_012294 (3.3 fold); XLOC_l2_008560 (3.3 fold); XLOC_009911y (3.2 fold); | Diagnostic | Prostate Cancer Vs Adjacent Normal | p<0.05 | Tissue | 25307116 |
1589 | SPRY4-IT1 | LncRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Adjacent Normal | p<0.05 | Tissue | 25307116 |
1590 | AK024556; XLOC_007697; LOC100287482; XLOC_005327; XLOC_008559; XLOC_009911; | LncRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Adjacent Normal | p<0.05 | Urine | 25307116 |
1604 | Full Length Androgen Receptor (AR-FL) | mRNA | Humans | NA | Prognostic | Progression-free survival Vs No Progression-free survival | p=0.0003 | Plasma | 31055861 |
1624 | KIF20A | mRNA | Humans | Upregulated in prostate cancer tissues compared with HR: 2.060 Pathways include: Kinesins, Aurora B signaling, Polo-like kinase 1 (PLK1) pathway, M phase pathway, MHC class II antigen presentation Prostate Cancer Vs No Prostate Cancer Diagnostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.8406 (95% CI: 0.6603-0.8256) NA p < 0.0001 1623 NA No NA NA Not validated on independent patient dataset 31031850 2019 CDK1 NA Expression Based mRNA Tissue Humans normal tissues | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p < 0.0001 | Tissue | 31031850 |
1625 | CCNB1 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p=0.0166 | Tissue | 31031850 |
1626 | BUB1 | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p < 0.0001 | Tissue | 31031850 |
1627 | CENPA | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p < 0.0001 | Tissue | 31031850 |
1628 | AURKB | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p =0.0002662 | Tissue | 31031850 |
1629 | CCNB2 | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p < 0.001469 | Tissue | 31031850 |
1630 | BIRC5 | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p =0.0001304 | Tissue | 31031850 |
1631 | AURKA | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p < 0.0001 | Tissue | 31031850 |
1632 | BUB1B | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p < 0.0001 | Tissue | 31031850 |
1633 | TTK | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p < 0.0001 | Tissue | 31031850 |
1634 | KIF20A | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p < 0.0001 | Tissue | 31031850 |
1636 | CDKN3 | mRNA | Humans | Upregulated in prostate cancer tissues compared with HR: 2.451 Pathways include: T cell receptor regulation of apoptosis Biochemical recurrence Vs No Biochemical Recurrence Prognostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.6493 NA p =0.0002558 1635 NA No NA NA Not validated on independent patient dataset 31031850 2019 KIF2C NA Expression Based mRNA Tissue Humans normal tissues | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p < 0.0001 | Tissue | 31031850 |
1637 | NCAPG | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p < 0.0001 | Tissue | 31031850 |
1638 | CDCA8 | mRNA | Humans | NA | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p =0.0001771 | Tissue | 31031850 |
1641 | TGM4; SOSTDC1; MPO; SPRR1A; KLF4; RNU3B1; RNU3B3; RNU3B4; MT-ATP6; MT-ATP8; TMEM170A; LYNX1; IFNL3; PPP1R3G; GPR15; UGT2A3; MED13L; DNAJC10; NPY; XIST; LST1; WNT9A; LRRN3; GPR45; IFIT1; YWHAQ; KIR3DL1; EPPIN; CRLF1; MAL2; MAP3K15; H1FX; | mRNA | Mice | Upregulated in prostate cancer tissues compared with NA Pathway include: Genes were related to 12 pathways: (i) Aryl hydrocarbon receptor (AHR) signaling, (ii) Bone metamorphosis signaling, (iii) Wnt/GSK-3β signaling, (iv) Glucocorticoid receptor signaling, (v) Immune cell signaling, (vi) Gas signaling, (vii) iNOS signaling, (viii) Hypoxia signaling, (ix) Wnt/β-catenin signaling, (x) Cancer metastasis signaling (xi) p38MAPK signaling, and (xii) Oxidative phosphorylation TRAMP mice Vs Non-Transgenic Mice Diagnostic Twenty week old TRAMP mice and non-transgenic littermates tissues were harvested NA NA NA NA p<0.05 1640 Microarrays No NA NA Validated on human patient cohort 30972102 2019 TOX4; RPL38; LSM12; RPL5; HAX1; ALPI; TCTE3; RPL7; MRTO4; HDAC1; UBE2H; KRT26; TNFSF10; DPPA2; PNLDC1; MRPS11; PFDN6; STOML2; VDAC1; RPS8; TDGF1; UBE2E2; GKAP1; RPL10A; RPS15; UMOD; RPL9; RPL30; NPNT; NR1I2; KRTAP16-1; H3F3A; H3F3B; MRPL34; CSE1L; ST6GALNAC1; UBE2Q2; RPS17; RPL35; GMCL1; NIP7; MSL2; EIF4A1; LASP1; LUZP4; EIF1AD; TUBB3; RPL34; RPL17; RPL23; RPL28; KIR3DL2; LMO2; NA; AOC3; H2AFZ; RPL37; TMSB10; AMY2A; AMY2B; PPIA; PPIH; BEGAIN; NT5C3A; RPS28; RPL27; IL24; COPS9; NEK2; SOCS2; UBL5; UBE2D3; VHL; RPL23A; AICDA; LDHA; CNEP1R1; RPL29; SPCS1; RPL41; SP110; PMP22; ARCN1; UQCRB; SLC25A19; UBE2N; SNRPE; ACKR1; RPL21; LEFTY2; RPL31; RPL35A; RPL7A; RPL39; NACA; SP140; MRPL23; VDAC3; VDAC1P5; ATP5L; DIMT1; GMCL1P1; ARFGAP2; RPL22;' NA Expression Based mRNA Tissue Mice normal tissues | Diagnostic | TRAMP mice Vs Non-Transgenic Mice | p<0.05 | Tissue | 30972102 |
1642 | ATP5L; ARFGAP2; DIMT1; GMCL1; MRPL34; RPL22; SP140; VDAC3 | mRNA | Mice | Upregulated in Gleason Grade 5 | Diagnostic | TRAMP mice Vs Non-Transgenic Mice | p<0.01 | Tissue | 30972102 |
1643 | KLF4; MPO; SOStdc1; SPRR1A; TGM4 | mRNA | Mice | Downregulated in TRAMP | Diagnostic | TRAMP mice Vs Non-Transgenic Mice | p<0.01 | Tissue | 30972102 |
1644 | TNFSF; RPL22; EIF4; SLC2A; LMO2/3; KRT; RPS21; RPS19; RPL21; NEK; PPP1R3; | mRNA | Humans | Upregulated in TRAMP | Diagnostic | prostate cancer vs. benign prostate | p<0.05 | Tissue | 30972102 |
1645 | GPR15; GPR45; TME; TGM4; KLF4; LRRN3; WNT; SPRR1A; TMEM; | mRNA | Humans | Upregulated in TRAMP | Diagnostic | prostate cancer vs. benign prostate | p<0.05 | Tissue | 30972102 |
1657 | MMP2 (Matrix Metalloproteinase-2) | mRNA | Humans | NA | Diagnostic | Prostate Cancer Vs Normal Prostate | p<0.05 | Tissue | 30917169 |
1658 | BASP1 (Brain Abundant Membrane Attached Signal Protein 1) | mRNA | Humans | Downregulated in High Grade PCa | Diagnostic | Prostate Cancer Vs Normal Prostate | p<0.05 | Tissue | 30917169 |
1659 | SNHG6 (small nucleolar RNA host gene 6) | LncRNA | Humans | Upregulated in High Grade PCa | Diagnostic | Prostate Cancer Vs Normal Prostate | p<0.05 | Tissue | 30911973 |
1660 | SNHG6 (small nucleolar RNA host gene 6) | LncRNA | Humans | Downregulated in PCa | Prognostic | Normal Prostate Vs T2 PCa Vs T3+T4 PCa | p<0.001 | Tissue | 30911973 |
1661 | SNHG6 (small nucleolar RNA host gene 6) | LncRNA | Humans | Upregulated in PCa | Prognostic | Normal Prostate Vs Gleason Score 6 Vs GS 7 VS GS 8 Vs GS 9+GS10 | p<0.001 | Tissue | 30911973 |
1662 | SNHG6 (small nucleolar RNA host gene 6) | LncRNA | Humans | Upregulated in PCa | Prognostic | Disease Free Survival Vs No Disease Free Survival | p=0.0365 | Tissue | 30911973 |
1663 | SNHG6 (small nucleolar RNA host gene 6) | LncRNA | Humans | Upregulated in T2 PCa and T3+T4 PCa | Diagnostic | Normal Cell Lines Vs PCa Cell Lines | p<0.001 | Cell Lines | 30911973 |
1664 | SNHG6 (small nucleolar RNA host gene 6) | LncRNA | Humans | Upregulated in GS 6,7,8,9+10 | Diagnostic | Prostate Cancer Vs Normal Prostate | p<0.05 | Tissue | 30911973 |
1694 | TTTY15-USP9Y | mRNA | Humans | Upregulated in PCa | Diagnostic | Positive Vs Negative Biopsy | p<0.001 | Urine | 26008593 |
1695 | TTTY15-USP9Y + PSA | mRNA | Humans | Downregulated in Gleason Pattern 4 and 5 | Diagnostic | Positive Vs Negative Biopsy | p<0.001 | Urine | 26008593 |
1696 | TTTY15-USP9Y | mRNA | Humans | Downregulated in Gleason Upgrade Patients | Diagnostic | Positive Vs Negative Biopsy | p<0.001 | Urine | 26008593 |
1729 | SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1; | mRNA | Humans | Upregulated in PCa: (PCa: 39.68 ± 30.00; No PCa: 15.04 ± 7.11) | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.05 | Tissue | 30286759 |
1730 | EMX2OS; LINC02137; LINC01116; LINC00839; AL161645.1; AC012123.1; AL354793.1; LINC02385; HOXBâ€AS3; AC005674.1; | LncRNA | Humans | Upregulated in High Risk PCa | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.05 | Tissue | 30286759 |
1732 | SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1; | mRNA | Humans | Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;] | Prognostic | High Risk Vs Low Risk PCa | p=0.00822 | Tissue | 30286759 |
1770 | PCA3 | mRNA | Humans | Upregulated in Stage T3-T4 | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | NA | Blood | 30334974 |
1771 | hK2 | mRNA | Humans | Downregulated in Stage T3-T4 | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | NA | Blood | 30334974 |
1822 | BUB1 | mRNA | Humans | Methylated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1823 | TPX2 | mRNA | Humans | Methylated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1824 | NCAPG | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1825 | UBE2C | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1826 | MELK | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1827 | CCNA2 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1828 | CCNB1 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1829 | CDK1 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1830 | E2F2 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1831 | DLGAP5 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1832 | TMEM206 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1833 | CDKN3 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1834 | SHMT2 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1835 | SRD5A2 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1836 | CSRP1 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1837 | PGM5 | mRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1838 | NFIB | mRNA | Humans | Downregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p<0.05 | Tissue | 30616540 |
1839 | HEATR5B (HEAT repeat containing 5B); DDC (Dopa decarboxylase, transcript variant 6); TAS1R3 (Taste 1 receptor member 3); XIAP (X-linked inhibitor of apoptosis, transcript variant 2); | mRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.05 | Tissue | 30890858 |
1840 | GABPB1-AS1 (GABPB1 antisense RNA 1); DDC (Dopa decarboxylase, transcript variant 6); HEATR5B (HEAT repeat containing 5B); CARD11 (Caspase recruitment domain family member 11, transcript variant 2); | mRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.05 | Tissue | 30890858 |
1841 | GABPB1-AS1 (GABPB1 antisense RNA 1); KRT5 (Keratin 5); NCS1 (Neuronal calcium sensor 1, transcript variant 2); COL17A1 ( Collagen type XVII alpha 1 chain); ANXA1 (Annexin A1); LGALS3BP (Galectin 3 binding protein); | mRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.05 | Tissue | 30890858 |
1842 | MT1IP (Metallothionein 1I, pseudogene (MT1IP), transcript variant 1); TRPT1 (tRNA phosphotransferase 1 (TRPT1), transcript variant 6); CHFR (Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase (CHFR), transcript variant 2); ZNF830 (Zinc finger protein 830); REXO1L2P (RNA exonuclease one homolog (S. cerevisiae)-like 2); SLC25A21 (SLC25A21 antisense RNA 1); | mRNA | Humans | Differentially Expressed | Prognostic | Tumor Stage T1C Vs T2 | p<0.05 | Tissue | 30890858 |
1843 | FXR2 (Fragile X mental retardation, autosomal homolog 2); GADD45GIP1 (Growth arrest and DNA-damage-inducible, gamma interacting protein 1); STX4 (Syntaxin 4, transcript variant 1); CALCOCO2 (Calcium binding and coiled-coil domain 2, transcript variant 1); BEST4 (Bestrophin 4); URI1 (Prefoldin-like chaperone, transcript variant 3); DCP2 (Decapping mRNA 2, transcript variant 3); | mRNA | Humans | Differentially Expressed | Prognostic | Tumor Stage T2 Vs T2a | p<0.05 | Tissue | 30890858 |
1844 | RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); SIRPA (Signal-regulatory protein alpha (SIRPA), transcript variant 3); COMP (Cartilage oligomeric matrix protein); SOD3 (Superoxide dismutase 3, extracellular); DIDO1 (Death inducer-obliterator 1, transcript variant 3); PRELP (Proline/arginine-rich end leucine-rich repeat protein, transcript variant 1); | mRNA | Humans | Differentially Expressed | Prognostic | Tumor Stage T2a Vs T2b | p<0.05 | Tissue | 30890858 |
1845 | BGN (Homo sapiens biglycan); RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); USP21 (Ubiquitin-specific peptidase 21, transcript variant 3); NR1D1 (Nuclear receptor subfamily 1 group D, member 1); ANGPTL2 (Angiopoietin-like 2); | mRNA | Humans | Differentially Expressed | Prognostic | Tumor Stage T2b Vs T2c | p<0.05 | Tissue | 30890858 |
1846 | SMAP2 (Small ArfGAP2 (SMAP2), transcript variant 2); TMSA (Prothymosin, alpha (PTMA), transcript variant 1); YY1AP1 (YY1 associated protein 1 (YY1AP1), transcript variant 6); DOCK9 (Dedicator of cytokinesis 9 (DOCK9), transcript variant 2); KITLG (KIT ligand (KITLG), transcript variant b); | mRNA | Humans | Differentially Expressed | Prognostic | Tumor Stage T2c Vs T3a | p<0.05 | Tissue | 30890858 |
1847 | FAM133DP (Family with sequence similarity 133 member D pseudogene); SAMM50 (Sorting and assembly machinery component 50 homolog, protein coding); OR4F13P (Olfactory receptor family 4 subfamily F member 13 pseudogene); | mRNA | Humans | Differentially Expressed | Prognostic | Tumor Stage T3a Vs T3b | p<0.05 | Tissue | 30890858 |
1848 | IKZF3 (IKAROS family zinc finger 3 (Aiolos), transcript variant 12); USP13 (Ubiquitin-specific peptidase 13 (isopeptidase T-3)); CLASP1 (Cytoplasmic linker associated protein 1, transcript variant 3); CEP112 (Centrosomal protein 112kDa, transcript variant 3); TSEN15 (tRNA splicing endonuclease subunit, transcript variant 1); FLVCR2 (Feline leukemia virus subgroup C cellular receptor family, member 2,transcript variant 2); GOLGA8B (Golgin A8 family, member B, transcript variant 1); ZNF438 (Zinc finger protein 438, transcript variant 1); SCARNA22 (Small Cajal body-specific RNA 22); LPPR1 (Lipid phosphate phosphatase-related protein type 1, transcript variant 2); PTGFR (Prostaglandin F receptor (FP), transcript variant 1); NREP (Neuronal regeneration related protein, transcript variant 1); | mRNA | Humans | Differentially Expressed | Prognostic | Tumor Stage T2c Vs T3/4 | p<0.05 | Tissue | 30890858 |
1876 | PD-L2 (Programmed death ligand 2) | mRNA | Humans | Methylated in PCa | Prognostic | Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival | p=0.01 | Tissue | 30321406 |
1877 | PD-L2 (Programmed death ligand 2) | mRNA | Humans | Methylated in PCa | Prognostic | Distant Metastatic Free Survival Vs No DMFS Survival | p=0.01 | Tissue | 30321406 |
1878 | PD-L2 (Programmed death ligand 2) | mRNA | Humans | Upregulated in PCa: []; Downregulated in PCa: [] | Prognostic | Prostate Cancer Specific Survival Vs No PCSS Survival | p<0.001 | Tissue | 30321406 |
1906 | AFP; AKR1C1; AKR1C3; AKR1C4; C1orf229; C5orf28; C5orf34; CCNE1; DNMT1; E2F3; ENSA; FBXO4; G6PD; KPNA2; LETM2; LGSN; MRPS30; OPLAH; OR4K15; OR4L1; PAIP1; SKP1; SPEF2; WDR70; ZNF124; ZNF280A; ZNF324B; ZNF669; ZNF695; | mRNA | Humans | Upregulated in Agressive PCa | Prognostic | Primary Prostate Cancer Vs Metastatic Prostate Cancer | p<0.05 | Tissue | 30401717 |
1907 | ANO7; NSA2; BOK; PDE8B; CECR6; PER3; CNNM1; PPP1R7; CNTNAP3; SCAMP1; COX15; SEMA4G; DMGDH; SLC7A8; DUSP1; TMEM18; EPHA7; TRIM8; FAM20C; TSLP; FOXC1; WDR41; ZNF658; GABRG3; GLB1L3; GLOD4; KCNMB1; LOC100128239; LOXL4; MTERFD2; NCAM1; NDN; | mRNA | Humans | Upregulated in Agressive PCa | Prognostic | Primary Prostate Cancer Vs Metastatic Prostate Cancer | p<0.05 | Tissue | 30401717 |
1908 | ADAM12; AURKA; AURKB; C7orf49; CDCA8; CENPF; CIT; DNMT3B; DYRK2; FANCD2; FGD1; GDAP1; GPI; GTSE1; HNRNPUL1; IPO9; KIF23; LIG1; NCAPH; NHSL1; PEG10; SKP2; TMEM65; TOP2A; TPX2; UBE2T; | mRNA | Humans | Upregulated in Agressive PCa | Prognostic | Primary Prostate Cancer Vs Metastatic Prostate Cancer | p<0.05 | Tissue | 30401717 |
1909 | ALDH1A3; APH1B; ATAD1; CTBS; CTSO; DHRS7; ESR1; FOXC1; MEIS2; NR4A1; PDE8B; RPS27L; SEC62; SPCS3; ZMAT1; | mRNA | Humans | Upregulated in Metastatic PCa | Prognostic | Primary Prostate Cancer Vs Metastatic Prostate Cancer | p<0.05 | Tissue | 30401717 |